Categories
Report

(Nasdaq: FMST)

***Sponsored by LFG Equities, Corp

Gantry 5

_______________________________

Hello Everyone,

We have a new company for you to research ahead of Thursday’s session.

This is a company that has closed green 4 of the last 5 and just bounced off of lows with significant momentum as FMST approahes tha critical $1 level. Every company wants to be sitting north of that.

Pull up FMST right away.

Foremost Clean Energy is a rapidly growing North American uranium exploration company dedicated to advancing the clean energy economy. Their projects consist of 10 prospective uranium properties strategically located within the world-renowned Athabasca Basin, totaling over 330,000 acres.

With drill–ready targets on identified conductors on important structural trends and proximal discoveries, their portfolio is well-positioned to capitalize on the growing demand for uranium as a crucial component of a sustainable energy future.

Foremost Clean Energy also maintains upside potential through a secondary portfolio of lithium projects with significant past drilling spanning 50,000+ acres primed for long-term development.

CATALYSTS

  • Extensive Uranium Asset Portfolio: Highly attractive diversified uranium exploration portfolio of shallow and deeper targets with a total of 10 properties spanning over 330,000 acres on 45 claims, with aggressive exploration plans
  • Proven Mining Jurisdiction and Prolific Uranium Region:Premier assets located in the Athabasca Basin in northern Saskatchewan, Canada, with robust infrastructure and known to host some of the world’s richest uranium deposits producing ~15% of world’s primary uranium with average grades ranging 10X to 100X higher than the global average
  • Strong Macro Tailwinds: Positioned to help enable the uranium market renaissance, with 20+ nations pledging to triple nuclear energy capacity by 2050 during a projected period of sustained structural uranium supply shortages
  • Key Uranium Funds and In-vest-ors: Significant number of strategic in-vest-ors including uranium and mining funds, institutions and insiders; $10.5Mn oversubscribed financing closed in November 2024
  • Incentives: Foremost Management and Board holds ~10.5% of the company’s shares outstanding.
  • Secondary Lithium Upside: Five Canadian lithium projects spanning 50,000+ acres with long-term development potential

‍

Foremost Enters the Uranium Exploration Industry Through an Option Agreement with Denison

On October 07, 2024, Foremost Clean Energy announced that further to the announcement on September 23, 2024, that it has now completed Phase One of its transaction (the “Transaction”) with Denison Mines Corp. (NYSE: DNN; TSX: DML acquiring 20% of Denison’s interest (the “Phase One Interest”) in 10 uranium exploration properties covering over 330,000 acres in the Athabasca Basin in Northern Saskatchewan (the “Exploration Properties”).

The acquisition was completed pursuant to an option agreement with Denison dated September 23, 2024 (the “Option Agreement”), which granted Foremost the option to acquire, through three phases, up to 70% of Denison’s interest in the Exploration Properties.

In addition, concurrent with the acquisition of Phase One Interest, Foremost has also:

• Appointed Mr. David Cates, the President and CEO of Denison, to Foremost’s board of directors; Mr. Cates has extensive expertise in the Canadian and international uranium mining industry from over a decade of senior management and financial experience in various roles with Denison;

• Appointed Andy Yackulic, Denison’s Vice President of Exploration, to its advisory board as a technical and geoscientific advisor. Mr. Yackulic has spent the past two decades of exploration focused in the Athabasca Basin region acquiring extensive experience with various geologic models for uranium mineralization, and has been working with Denison since 2020. Previously, he spent 12 years at Cameco Corporation in various roles and led the exploration team that discovered the Fox Lake uranium deposit. Mr. Yackulic holds a Bachelor of Science in Geology from the University of Saskatchewan, is a member of the Association of Professional Engineers & Geoscientists of Saskatchewan (APEGS), and is a Qualified Person in accordance with the requirements of National Instrument 43-101 – Standards of Disclosure for Mineral Projects;

• Entered into an investor rights agreement with Denison; and

• Become the operator of the Exploration Properties.

The Exploration Properties are comprised of 45 claims covering an aggregate area of 332,378 acres (134,509 hectares) within the Athabasca Basin region of northern Saskatchewan, which is known for its prolific history of large high-grade uranium discoveries and operating mines—currently producing ~15% of the world’s primary uranium supply. The portfolio of properties can be grouped into seven (7) properties situated in the eastern Athabasca Basin (Murphy Lake South, Hatchet Lake, Turkey Lake, Torwalt Lake, Marten and Wolverine) and three (3) blue sky properties , which consist of roughly 102,000 hectares staked in October 2023 over regional structures and/or structural corridors (Blackwing, CLK and GR).

A map of a large areaAI-generated content may be incorrect.

Fig 1. Map of Foremost’s Uranium Properties With Nearby Mills, Mines and Deposits

Collaboration with Denison

Denison (TSX: DML) (NYSE American: DNN) is a leading Athabasca Basin-focused uranium mining, development, and exploration company. Denison has a significant team of technical experts based in its office in Saskatoon, Saskatchewan, and this best-in-class team is ideal for supporting Foremost with its technical, operating and corporate initiatives. With the completion of Phase 1 of the Option Agreement, Denison became the largest shareholder of Foremost, holding ~19.95% of the shares outstanding and will retain an

Foremost is project operator during the term of the Option Agreement and will conduct the exploration programs with its geological team led by Dahrouge Geological Consulting, under the guidance of Jody Dahrouge. Mr. Dahrouge has a long history of uranium exploration and discovery, which includes the generation of several projects on behalf of Strathmore Minerals Corp. and its successors, including the J Zone (now the Tthe Heldeth Túé deposit) on the Waterbury Lake property, the JR Zone on the Patterson Lake North property and the Triple R Zone at the Patterson Lake South property. As a past President and COO of Fission Energy Corp. (“Fission Energy”), Jody played a key role in the acquisition and exploration of Fission Energy’s exploration property portfolio, which culminated with the eventual acquisition of Fission Energy by Denison in 2013.

Foremost Clean Energy Commences 2025 Drilling Program at Hatchet Uranium Project

The Hatchet Drill Program is expected to test for extensions of known uranium mineralization and new targets based on previously identified anomalous pathfinder elements and hydrothermal alteration

VANCOUVER, British Columbia, April 04, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) an emerging North American uranium and lithium exploration company, is pleased to announce the commencement of its 2025 exploration drill program (the “Drill Program”) at the Hatchet Lake Uranium Project(“Hatchet“), located in the world-renowned Athabasca Basin of northern Saskatchewan. The 2,000 metre helicopter-supported diamond drill program commenced recently and is being conducted on behalf of Foremost by Dahrouge Geological Consulting (“DGC”). Drill testing during this program is expected to evaluate the project’s top exploration prospects at both the Tuning Fork target area (“Tuning Fork”) and Richardson target area (“Richardson”).

“We are excited to commence this fully-funded drill program at Hatchet.” said Jason Barnard, Foremost’s President and CEO, “This program represents a significant step forward for Foremost, launching our first exploration drill program in the Athabasca Basin, designed to evaluate several discovery-ready target areas on well-situated and advanced exploration project that is part of our unique collaboration with Denison Mines Corp. (‘Denison’). Our drill targets for this program have been designed to test interpreted structures and conductive breaks identified based on the wealth of historic exploration already completed on this exciting property.”

Hatchet is located within 1.5 km of the Athabasca Basin margin, which results in shallow sandstone cover (less than 220 metres) and corresponding shallow exploration targets, enabling efficient and cost-effective drill testing. The upcoming 2025 drill campaign plans to capitalize on this advantage, including multiple drill holes to advance the evaluation of several target areas – each of which are highly prospective and have potential for discovery or which will benefit in future drill programs from additional reconnaissance.

Tuning Fork

The shallow drill targets at Tuning Fork (Figure 1) comprise 1,000 m of the planned drilling with an unconformity depth ranging from 120 – 160m. Historical and the 2024 drilling program have identified prominent structures and alteration along conductive trends identified via ground electromagnetic (“EM”) surveys that are coincident with previously identified mineralization that is located near structures at the unconformity. A folded conductive package of graphitic metasediments adjacent to the structure underscores the key elements for uranium mineralization.

Tuning Fork - 2025 drilling target locations and proposed drillholes

Figure 1 – Tuning Fork – 2025 drilling target locations and proposed drillholes

Richardson

The balance of drilling at Hatchet during this program (~1,000 m) is planned to consist of follow up drilling and reconnaissance drilling at the Richardson target area. A series of discrete linear EM conductive anomalies (~7 km in total length) comprise the Richardson target area. Historical drilling (Figure 2) has confirmed the presence of mineralization along the conductive trend at and immediately below the unconformity. Follow up drilling is designed to test the continuity of mineralization along strike and obtain structural data on mineralized structures identified in historical holes. Additional drilling is expected to test certain prospective unexplored conductive trends to evaluate the potential to host uranium mineralization.

Richardson Trend - 2025 drill targets and proposed drillholes

Figure 2 – Richardson Trend – 2025 drill targets and proposed drillholes

Qualified Person

The technical content of this news release has been reviewed and approved by Jordan Pearson, P. Geo., Project Geologist for Dahrouge Geological Consulting Ltd., and a Qualified Person under National Instrument 43-101, who has prepared and reviewed the content of this press release.

A qualified person has not performed sufficient work or data verification to validate the historical results in accordance with National Instrument 43-101. Although the historical results may not be reliable, the Company nevertheless believes that they provide an indication of the property’s potential and are relevant for any future exploration program.

NEWS

‍
Foremost Clean Energy Announces National Marketing Campaign

2 days ago

Foremost Clean Energy to Conduct Airborne Geophysics Survey Over its CLK Uranium Property

Apr 14, 2025

Foremost Clean Energy Receives Nasdaq Notification Regarding Minimum Bid Price Requirement

Apr 11, 2025

Foremost Clean Energy Commences 2025 Drilling Program at Hatchet Uranium Project

Apr 4, 2025

Foremost Clean Energy Commences Site Preparation for 2025 Drill Program at Hatchet Uranium Project

Mar 27, 2025

Foremost Clean Energy Announces $6.5 Million Uranium Exploration Program Across the Athabasca Basin

Mar 12, 2025

Foremost Clean Energy Reports Multiple Intercepts of Uranium Mineralization from Hatchet Assays

Feb 20, 2025

Foremost Clean Energy to Attend Prospectors & Developers Association of Canada (PDAC) 2025 Convention

Feb 13, 2025

Foremost Clean Energy Ltd. Announces Participation in Red Cloud’s 13th Annual Pre-PDAC Mining Showcase

Feb 10, 2025

Foremost Clean Energy Announces Commencement of Trading of its Spin-Out, Rio Grande Resources

Feb 7, 2025

‍

MANAGEMENT TEAM

A person in a suitAI-generated content may be incorrect.
A person in a suit and tieAI-generated content may be incorrect.

‍JASON BARNARD

CEO And President, And Non-Independent Executive Board Member

Jason Barnard

Mr. Barnard has over 31 years of capital markets experience. Since 2004, he has been self-employed as a private investor where he has been directly involved in raising over $500 million dollars for mining and exploration companies with a focused expertise on Canadian base metal companies.

Mr. Barnard started his career with McDermid St. Laurence Securities in 1991 as a stockbroker with primary focus in mining, and mining exploration companies. Mr. Barnard then worked at Canaccord Genuity from 1997 until 2004. Mr. Barnard holds a Bachelor of Arts degree with a major in Economics from Carlton University and has obtained The Canadian Securities Course license in 1990. He first started working with and financing Foremost Lithium, previously known as Far Resources, with founder, and President Keith Anderson in 2016 and is the Company’s largest shareholder.

David Cates

Independent Director

David Cates

Mr. Cates is a Chartered Professional Accountant (CPA, CA) and holds Master of Accounting (MAcc) and Honours Bachelor of Arts (BA) degrees from the University of Waterloo. Mr. Cates has extensive expertise in the Canadian and international uranium mining industry from over a decade of senior management and financial experience in various roles with Denison.

Mr. Cates was appointed President & CEO of Denison in 2015, having previously served as the company’s Vice President, Finance & Tax and Chief Financial Officer. Prior to joining Denison in 2008, Mr. Cates held positions at Kinross Gold Corp. and PwC LLP. Mr. Cates also serves as a Director of the Canadian Nuclear Association and of SkyHarbour Resources Ltd.

‍

Mark cropped

JODY DAHROUGE, B.SC., SP.C., – P. GEOL.

Geological Advisor

Jody Dahrouge

Mr. Dahrouge has been the President of Dahrouge Geological Consulting Ltd., a North American mineral exploration, consulting, and project management group, since 1988. He is a professional geologist with over 30 years’ experience and holds Bachelor of Science degrees in geology and computing science, both from the University of Alberta.

Mr. Dahrouge has been involved in all aspects of mineral exploration and development for a wide variety of commodities worldwide. Dahrouge Geological Consulting Ltd. has been instrumental in a multitude of grassroots discoveries across a wide variety of commodities and currently has boots on the ground on multiple Canadian and American projects

A person in a suit and tieAI-generated content may be incorrect.

MARK FEDIKOW PH.D. P.GEO. CPG

Geoscientific Advisor

Mark Fedikow

Dr. Fedikow has over 40 years of experience as an exploration geochemist and a mineral deposits geologist working in both private and public sectors. He is a Fellow at the Association of Applied Geochemists, where he’s previously worked as a councilor. Dr. Fedikow has also served on numerous industry-related committees. He also pioneered the application of regional multimedia geochemical and mineralogical surveys in support of base and precious metal and diamond exploration in Manitoba.

During his 45-year career he has worked for a variety of junior and major mining exploration and mining companies and for the Manitoba Geological Survey as Chief Geologist of the Mineral Deposits Section. In 2001 he received the Provincial Geologists gold medal, a Canadian national award for excellence in the geosciences.

In 2002 Mark left the Manitoba Geological Survey to start his own company (Mount Morgan Resources Ltd.) providing consulting services to the metal and hydrocarbon exploration industry. He is currently registered as P.Eng. and P.Geo. with Engineers Geoscientists Manitoba (“EGM”), P.Geo. with the Northwest Territories and Nunavut Association of Professional Engineers and Geoscientists (NAPEG) and as a Certified Professional Geologist (C.P.G.) with the American Institute of Professional Geologists (“A.I.P.G.”), Westminster, Colorado, U.S.A.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND ONE HUNDRED SEVENTY FIVE USD BY LFG EQUITIES CORP FOR A ONE DAY FMST AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

CYCU

***Sponsored by Corporate Ads, LLC

2024 Total Revenue of 17.8 Million with Adjusted EBITDA of $2.3 Million, +58.9% y/y with Expanded Margin of 12.9% vs $1.4 Million in FY2023 & Net Income of $1.2 Million Marking First Full Year of Net Profitability

________________________

Hello Everyone,

We have another company that we need to get on your radar as we head into Wednesday’s session.

This is another company that we have never profiled on our newsletter before.

Right now it is hovering around .50 and they JUST dropped some big contract news that is still circulating right now.

Pull up CYCU on your screen after you write it down.

We feel that this one could potentially spark a squeeze given the catalysts in play right now surrounding this one. It has been pummeled since it IPO’d back in February. Bad news if you participated in the IPO but potentially good news if you are looking at here below .45. This one is sitting just a hair off of the 52 week low. Has this one potentially bottomed out for now? We are going to be watching close because this one certainly has provided a lot of volatility. Take a look at what I am seeing:

CYCU has put out some substantial headlines since it started trading that cannot be ignored. CYCU has been announcing several multi-million dollar contracts.

Cycurion, Inc. (Nasdaq: CYCU) is a tech-enabled cybersecurity firm that serves some of the most complex government agencies and corporations in the world including Fortune 100 and 500 Companies. Founded by internet pioneer Emmit McHenry — who directly oversaw the first internet protocols and the creation of .com domains — CYCU brings an unparalleled blend of vision, technology, and experience to every project. More than just an MSSP or strategic advisor, CYCU is a full-service security partner capable of guiding any organization through the modern cyber threat landscape.

Cybersecurity has become an increasingly critical issue as illustrated by many top level media sources devoting high profile features on the subject.

CYCU is committed to surpassing expectations and delivering incomparable value to itsclients and partners. CYCU achieves this goal by providing Network Communications and Information Technology Security services and solutions that are custom-tailored to the client’s environment, as well as level of need. CYCU is built on a foundation of experts in Network Communications and Information Technology who possess unrivaled security expertise and experience.

The flagship Cycurion ARx platform is a unified cybersecurity solution for protecting critical digital assets. Multi-layer protection is focused on inspecting requests to and responses from a digital asset. This non-invasive approach wraps around a digital asset — without hardware requirements or cloud installations — while keeping the client’s IP completely private. With every request inspected, malicious threats are logged and blocked in real-time before reaching the asset. This CYCU multi-layer model of cybersecurity is intended to thwart potential attackers via an expanding set of protective layers.

Cycurion, Inc. Announces $6 Million Contract Award by Major Municipal Transportation Agency

Award demonstrates Cycurion’s growth in public, transportation sector through comprehensive IT and cybersecurity services offering

MCLEAN, Va., April 29, 2025 (GLOBE NEWSWIRE) — Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces it has been awarded a $6 million contract by a major municipal transportation agency. Under this contract, Cycurion will deliver a wide range of professional consulting services, including Audit and Cybersecurity Services, Organizational Change Management Consulting, Data Analytics, and Information Technology Services. The Scope of Work also potentially includes the integration of Cycurion’s proprietary ARx platform to further enhance operational and cybersecurity capabilities.

Cycurion brings extensive transportation sector expertise, combined with a strong track record in defining and measuring organizational performance to address deficiencies. Specific services provided will include Risk and Vulnerability Assessments, Regulatory Compliance Analysis, Enterprise Cybersecurity Strategy Development, Testing, and Vulnerability Management.

“The contract with this major municipal transportation agency demonstrates the utility of our full range of capabilities within the municipal transportation sector, and represents an important expansion into that vertical,” said L. Kevin Kelly, CEO of Cycurion. “This award further highlights our strategic growth and ongoing commitment to helping our clients manage risk, drive innovation, and achieve operational excellence. We look forward to leveraging our full team’s broad resources and deep industry expertise to deliver best-in-class solutions.”

Cycurion continues to drive its overarching strategy to expand its presence among the broader public sector services market – including that of transportation – along with the broadening of its service offerings to include higher value IT and leading cybersecurity services.

‍

Cycurion, Inc. Announces Expansion into Latin America Through Partnership with LSV-TECH International of Colombia

Partnership Extends Cycurion’s Sales Presence Into 135 Countries via LSV’s Strategic Partnership with Nokia

MCLEAN, Va., April 22, 2025 (GLOBE NEWSWIRE) — Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces a partnership with LSV-TECH International Consortium for Digital Transformation and Technological Innovation to expand the new Managed Security Services Platform (MSSP) Cyber Shield into Latin Americaand strengthen cross-border interconnections globally.

The partnership is commencing through a pilot program with several Colombian universities to showcase the new MSSP Cyber Shield. LSV-TECH has long-term, established relationships with several higher education institutions in Colombia, wherein strategic alliances aimed at developing digital talent and strengthening capabilities in new technologies have been developed. Its academic partners include the Popular University of Cesar, the University of La Guajira, the University of North Barranquilla, the University of Valle Cali, the Intenalco University Cali, the Antioquia University Medellin, the University of Cartagena, the Major University Institution of Cartagena, the Rafael Núñez University, the Technological University of Bolívar, and the University of Sinú. These relationships allow for joint efforts in applied research, professional internships, training in emerging technologies, AI, and open innovation programs.

With an established footprint predominantly in Latin America that will have an estimated $5 billioncybersecurity market in 2027 – Brazil, Spain, Peru, Chile, and Colombia – along with its strategic global partnership with Nokia, acting as a primary IT service provider in over 135 countries, LSV-TECH plays a critical role in implementing and maintaining essential technological solutions that enhance global connectivity. Cycurion’s partnership with LSV-TECH greatly enhances the Company’s high impact, yet cost-effective, MSPP Cyber Shield solution sales reach, enabling it to penetrate a vast network of potential government, education, and enterprise clients globally.

Cycurion Vice President Michael Phillips, emphasizing the significance of the Cycurion/LSV partnership, stated, “This partnership is a pivotal opportunity for Cycurion, as it creates additional opportunities to expand our business in a critical global market, while also expanding our capabilities for current and future clients.” Highlighting the strategic advantage of LSV’s Latin American presence, he continued, “Cybersecurity is a common challenge worldwide and partnering with LSV-TECH in Columbia provides an entry point into the Latin American market from which we then expect to develop further expansion and growth via the Nokia connection.”

About LSV-TECH LSV-TECH was established in 2014. It is a trusted leading consortium in the field of digital transformation, which has consolidated its leadership by developing advanced technological solutions in key areas, such as cybersecurity, robotic process automation (RPA), the Metaverse, the Internet of Things (IoT), Artificial Intelligence (AI), and Big Data. Its comprehensive and adaptive approach enables organizations across diverse sectors to address the challenges of the digital age efficiently, securely, and with a forward-thinking vision.

LSV-TECH projects itself as a worldwide key player in the international technology ecosystem, combining innovation, global partnerships, and a commitment to developing local capabilities. Its consortium model offers a robust platform for advancing digital transformation in both the public and private sectors, serving as a benchmark in the convergence of technology, talent, and sustainability.

Cycurion, Inc. Expands Partnership with Journal Technologies, Secures $22 Million Contract with State Police Agency

FALLS CHURCH, Va., April 08, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU), a trailblazer in advanced cybersecurity and information technology solutions, today announces an expanded partnership with Journal Technologies, a leading provider of case management and operational solutions for justice agencies worldwide. Together, the companies have been awarded a $22 million multi-year contract to deliver a state-of-the-art criminal justice case management system to a State Police agency, reinforcing Cycurion’s leadership in securing critical justice infrastructure.

The web-based solution, powered by Journal Technologies’ robust eSeries Framework platform, provides comprehensive case management, tracking, and reporting capabilities. Designed to streamline the initiation, planning, execution, control, and reporting of prosecution and investigative activities, the system prioritizes cybersecurity resilience to protect sensitive data and operations from escalating cyber threats. With decades of justice-sector expertise embedded in the eSeries Framework, the platform delivers document management, workflow automation, database organization, forms processing, and seamless third-party integrations enhanced by Cycurion’s cutting-edge security expertise.

“Cycurion’s partnership with Journal Technologies provides the tools to empower the State Policewith a solution that not only optimizes operational efficiency but also sets a new standard for cybersecurity in the justice sector,” said Kevin Kelly, CEO of Cycurion, Inc. “This collaboration reflects our commitment to safeguarding critical systems while driving innovation across the offender life cycle.”

AI-Powered Cybersecurity ExpansionThis landmark contract aligns with Cycurion’s strategic vision to expand its cybersecurity business, with artificial intelligence (AI) at the core of its growth strategy. By embedding AI-driven capabilities into its justice-sector offerings, Cycurion is redefining how government and law enforcement agencies combat cyber threats. The company’s Cyber Shield MSSP (Managed Security Service Provider) solution, now enhanced with AI, delivers advanced threat detection, automated response protocols, and predictive vulnerability analysis—ensuring unparalleled protection for mission-critical operations. This $22 millionengagement underscores Cycurion’s dedication to scaling its AI-powered cybersecurity solutions, cementing its position as a market leader in delivering transformative, high-impact security to the public sector.

Drawing on its extensive experience in integrated justice and data administration, Cycurion strengthens the eSeries Framework with industry-leading security measures. As an active member of the Integrated Justice Information Systems (IJIS) Institute, the National Sheriff’s Association, and standards committees of the National Information Exchange Model (NIEM), Cycurion shapes the future of secure data exchange and justice technology. The Cyber Shield MSSP solution offers tailored, AI-enhanced protections across the offender life cycle, safeguarding sensitive data and operations in an increasingly digital world.

NEWS


Cycurion, Inc. Announces $6 Million Contract Award by Major Municipal Transportation Agency

2 hours ago

Cycurion, Inc. Announces Expansion into Latin America Through Partnership with LSV-TECH International of Colombia

Apr 22, 2025

Cycurion Reports Full Year 2024 Financial Results

Apr 17, 2025

Cycurion Announces Reginald S. Bailey, Sr Joins Board of Directors

Apr 10, 2025

Cycurion, Inc. Expands Partnership with Journal Technologies, Secures $22 Million Contract with State Police Agency

Apr 8, 2025

Cycurion Announces Industry Veteran Kevin O’Brien Joins Board of Directors

Apr 3, 2025

Cycurion Announces Launch of Cyber Shield, a Comprehensive Managed Security Services Platform

Mar 25, 2025

Cycurion CEO Kevin Kelly Provides Corporate Update in Letter to Stockholders

Mar 18, 2025

Cycurion (Nasdaq: CYCU) Partners with CentralSquare Technologies to Provide Public Safety IT Services Across the Country

Mar 6, 2025

Cycurion (Nasdaq: CYCU) Awarded Three Multi-Year Contracts Highlighting Growth and Innovation

Mar 5, 2025

Cycurion Announces U.S. Launch of its AI Driven SaaS ARx Platform Targeted to the Corporate Sector

‍Mar 4, 2025

‍

MANAGEMENT TEAM

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FOUR THOUSAND FIVE HUNDRED USD BY CORPORATE ADS LLC FOR A ONE DAY CYCU AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

ALBT

***Sponsored by Shore Thing Media, LLC

Read the Investor Presentation HERE

________________________

Hello Everyone,

We have another company that we want you to put on your radar ahead of Tuesday’s session.

You will remember this one. We just took a look at it a few weeks back at this one when it was trading under 4 bucks.

It traded as low as 3.60 that session and less than a week later it was 5.25.

Since then it has pulled back, offering up another opportunity for our members to research this one.

Put ALBT on your radar and get ready for a potential action packed week.

This one went through a 15-1 reverse split back in October, reducing the float on this to under 1M according to FINVIZ.

You are going to want to keep a close eye on this one heading into the bell.

Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products. Avalon is currently marketing the Keto Air breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the company owns and operates commercial real estate.

‍

Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement

YOOV Achieves 59.1% Annual Revenue Growth, Reporting Unaudited Revenue of $45.7 Million with Net Income of $3.4 Million for Calendar Year 2024, Versus Unaudited Revenue of $28.7 Million with Net Loss of $2.4 Million for Calendar Year 2023

Upon Consummation of the Merger, Pending Nasdaq Approval, the New Combined Company is Expected to Trade Under the Nasdaq Symbol “YOOV”

FREEHOLD, N.J., March 10, 2025 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has entered into a definitive merger agreement with YOOV Group Holding Limited (“YOOV”), a leading provider of business artificial intelligence (“AI”) automation solutions. Under the agreement, YOOV will merge with and into Avalon (the “Proposed Merger”). The combined company is expected to operate under the name YOOV, Inc. and expected to continue trading on The Nasdaq Capital Market under the symbol “YOOV”. The transaction is expected to close in the third quarter of 2025. The completion of the Proposed Merger is subject to several conditions, including the approval of the stockholders of Avalon.

YOOV’s highly advanced AIaaS (Artificial Intelligence as a Service) platform is transforming enterprise workflow management, communication, and operational efficiency. The company’s proprietary AIaaS platform makes AI accessible and empowers businesses of all sizes to streamline processes, optimize resources, and improve productivity through intelligent automation. With a strong emphasis on scalability and flexibility, YOOV enables businesses to adapt their platforms to their specific needs, thereby maximizing the impact of automation across various sectors.

Driven by increasing demand for AI-powered business automation, YOOV had unaudited revenue of $45.7 million and net income of $3.4 million for the calendar year ended December 31, 2024, compared to unaudited revenue of $28.7 million and a net loss of $2.4 million for the calendar year ended December 31, 2023. In addition, YOOV had unaudited revenue of $29.6 million and net income of $1.3 million for the fiscal year ended March 31, 2024 compared to unaudited revenue of $21.5 million and a net loss of ($527,403), for the fiscal year ended March 31, 2023.

Dr. David Jin, M.D., Ph.D., CEO of Avalon GloboCare, stated, “We believe this transaction is in the best interest of our shareholders, providing a unique opportunity to unlock value and participate in the future of AI-driven automation. We believe that YOOV’s advanced AI technology, strong market presence, and rapid growth trajectory represent a compelling market opportunity. We believe this merger has the potential to drive innovation, scalability, and long-term shareholder value.”

Phil Wong, Co-Founder and CEO of YOOV, commented, “We believe this merger will provide us with a foundation to accelerate our growth, extend our impact across industries, and strengthen our ability to drive innovation. We look forward to leveraging this opportunity to create lasting value for our respective businesses and shareholders.”

About the Proposed Transaction, Management & Organization

Under the terms of the merger agreement, subject to stockholder approval, on a pro forma basis, post-merger Avalon equityholders are expected to collectively own between approximately 2.5% to 2.2% and YOOV equityholders are expected to collectively own between approximately 97.5% and 97.8% of the common stock of the combined company on a pro forma basis, depending on the market price of Avalon’s common stock at the time of the completion of the merger.

The merger agreement has been approved by the boards of directors of both companies and is subject to stockholder approval of both companies and other customary closing conditions. The proposed merger is expected to close in the third quarter of 2025.

Following the merger, Phil Wong will become Chairman, Chief Executive Officer, and President. The merger agreement provides that the board of directors of the combined company will be composed of seven members, with five members initially designated by YOOV and two members initially designated by Avalon.

Roth Capital Partners acted as the exclusive financial advisor to Avalon in connection with the merger.

For further information regarding the terms and conditions contained in the Merger Agreement, please see Avalon’s current report on Form 8-K, which was filed with the U.S. Securities and Exchange Commission in connection with the Proposed Merger.

The financial information contained in this press release is unaudited and is based on preliminary internal data of YOOV. In addition, the information for the fiscal years ended March 31, 2023, and March 31, 2024, is subject to completion of YOOV’s audit. This financial information is subject to change and may differ from the final audited financial statements. Avalon and YOOV do not undertake any obligation to update this information, except as required by applicable law. Readers are cautioned not to place undue reliance on this unaudited financial information, as it may not provide a complete or accurate picture of YOOV’s financial condition or results of operations.

About YOOV Group Holding

YOOV is an Artificial Intelligence (AI) as a Service (AIaaS) platform specializing in intelligent business automation, integrating AI, process and data into one platform to make business operations easy, efficient, and effortless. YOOV empowers businesses of all sizes to use AI without the need for extensive resources or technical expertise. By seamlessly integrating robotic process automation (RPA) with advanced AI capabilities, YOOV delivers versatile solutions tailored to meet the diverse needs of various industries. Over the years, YOOV has been growing rapidly with a strong global presence.

Beyond its core AI automation solutions, YOOV extends its offerings into financial and insurance services through its subsidiaries, YOOV Capital Limited and YOOV Insurance Services Limited. These subsidiaries leverage YOOV’s commercial data insights to provide credit evaluation and insurance brokerage services, further enhancing the YOOV ecosystem and delivering added value to clients.

Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series

KetoAir Now In Stock at All Three Pounds Transformation Clinics in Connecticut

FREEHOLD, N.J., April 01, 2025 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced that it has partnered with Pounds Transformation Clinics, led by Dr. Charles Cavo, a member of the Zero to Keto Affiliate Marketing Program, to launch the “BrAce 4 Impact Challenge Series.” This new collaboration has already debuted its inaugural challenge in conjunction with Pounds Transformation’s 4-week Diet Challenge, incorporating KetoAir™ breathalyzer devices as a motivational tool. KetoAir™ devices are now available on consignment at all three Pounds Transformation locations in West Hartford Center, Southington, and Glastonbury, Connecticut.

Following the successful conclusion of the 4-week BrAce 4 Impact Challenge Pilot on March 18, 2025, Pounds Transformation is kicking off the first official BrAce 4 Impact Challenge starting April 1, 2025. “I saw a patient today from the BrAce 4 Impact Challenge pilot who is doing extremely well,” said Dr. Charles Cavo. “She uses the KetoAir™ three times a day and has never experienced this level of weight loss before. Her BrAce readings remain around 12ppm, and she’s never felt better. The KetoAir™ keeps her ‘honest’ and on track. With the level of results our patients are achieving with the help of the KetoAir™, it is our intent to begin new BrAce 4 Impact Challenges every six weeks,” added Dr. Cavo. To further support participants, Pounds Transformation has assigned a dedicated coach as the daily point of contact throughout the Challenge Series.

Pounds Transformation is a Connecticut-based health and wellness clinic focused on long-term weight management. Their programs address the root causes of weight gain through evidence-based interventions, ongoing support, and regular monitoring of key health markers.

KetoAir™ is a handheld breathalyzer, specifically engineered for ketogenic health management (United States FDA registration number: 3026284320). KetoAir™ measures an individual’s breath acetone concentration (BrAce), a ketone body that rises as fat oxidation increases. By leveraging the nano-sensor-based technology, the KetoAir™ breathalyzer is designed to assess the ketosis status of its individual user and is accessible on both the Apple App Store and Google Play Store.

“We are very pleased with the expansion of our partnership with Pounds Transformation clinics,” said David Jin, M.D., Ph.D., CEO of Avalon GloboCare. “It’s rewarding to see the KetoAir™ device have such a positive impact on their patient programs, supporting real-time, personalized insights that empower individuals on their wellness journey. This partnership highlights our shared commitment to delivering innovative, accessible tools that improve health outcomes and encourage long-term lifestyle changes.”

“Integrating the KetoAir™ Breathalyzer into our programs allows our patients to track their ketone levels in real time, helping them stay motivated and engaged in their daily routines,” said Dr. Charles Cavo, Co-founder of Pounds Transformation. “Many of our patients have struggled with weight loss for years. KetoAir™ provides immediate feedback that helps validate their progress, reinforce positive behavior, and improve accountability. It’s become a valuable tool in helping our patients understand their bodies and take control of their health in a sustainable way.”

Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China

FREEHOLD, N.J., April 10, 2025 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has been granted the patent right and Certificate of Invention for its CAR-T and CAR-NK cell technology by the China National Intellectual Property Administration (CNIPA). The patent, entitled “Artificial Immunosurveillance Chimeric Antigen Receptor and Cells Expressing the Same” and filed under application number CN2020800152050 and issued as No. CN 114502188 B, marks a milestone in the Company’s global intellectual property strategy. The patent term extends 20 years from the issuance date, effective April 4, 2025, and reflects Avalon’s continued commitment to pioneering immunotherapy technologies for global markets.

This patent, co-developed with Hong Kong-based Arbele Limited, represents an advancement in chimeric antigen receptor (CAR)-based therapies and broadens Avalon’s intellectual property portfolio. Already protected in the U.S. and other territories under the Patent Cooperation Treaty (PCT), this newly issued Chinese patent further reinforces Avalon’s intellectual property position in the global market.

The patent covers innovative technology designed to enhance the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-Natural Killer (NK) cells. Key features of the patent include:

  • Bispecific Anti-CD19xCD22 CAR: A novel design that targets both CD19 and CD22 antigens for purposes of reducing the risk of tumor escape due to antigen loss.
  • Localized Cytokine Induction: A mechanism that triggers cytokine responses only at the site of tumor engagement, for purposes of improving CAR cell cytotoxicity, survival, and proliferation, while also activating the patient’s own anti-tumor immune response.

“The official issuance of this patent in China not only expands our global intellectual property footprint but also strengthens our position in cell-based immunotherapy,” said David Jin, M.D., Ph.D., Avalon’s CEO. “”With 20 years of protection secured through this recent patent grant, we continue to demonstrate our commitment to advancing intellectual property that supports innovative cancer treatments.”

‍

NEWS


Avalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs’ Fitness Challenge with KetoAir

Apr 15, 2025

Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China

Apr 10, 2025

Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series

Apr 1, 2025

Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement

Mar 10, 2025

Avalon GloboCare Receives Notice of Allowance for Groundbreaking CAR-T and CAR-NK Cell Technology in China

Feb 18, 2025

Avalon GloboCare Regains Compliance with Nasdaq Continued Listing Requirements

Nov 21, 2024

Avalon GloboCare Launches “BrAce for Impact” Affiliate Marketing Program for the KetoAir Breathalyzer Device

Nov 18, 2024

Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales

Oct 31, 2024

Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

Oct 25, 2024

Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

Oct 24, 2024

Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

Oct 25, 2024

Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

Oct 24, 2024

Avalon GloboCare to Sponsor Keto Pa-LOU-za 2024 Conference and Showcase KetoAir Breathalyzer Device

Oct 9, 2024

MANAGEMENT TEAM

David Jin

Chief Executive Officer, President and Director

Dr. David Jin, MD, PhD, a director and Chief Executive Officer of the Company and AHS. From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology. Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University. Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters. Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology. Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015.

Meng Li

Chief Marketing Officer, Secretary

Ms. Li served on the Company’s board from October 2017 through July 2018 and was re-appointed in February 2019. Ms. Li has over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenith Media (a Publicis Group company) from 2000 to 2006 as Senior Manager. Ms. Li received a Bachelor of Arts in International Economic Law from Dalian Maritime University in China.

Luisa Ingargiola

Chief Financial Officer

Luisa Ingargiola is the Company’s Chief Financial Officer. Ms Ingargiola has significant experience serving as Chief Financial Officer or Audit Chair for multiple NASDAQ and NYSE companies. She currently serves as Director and Audit Chair for several public companies including ElectraMeccanica (NASDAQ:SOLO), Dragonfly Energy (NASDAQ:DFLI)and Vision Marine Technolgoies (NASDAQ:VMAR)). From 2007 through 2016, Ms. Ingargiola served as the Chief Financial Officer and then Director at MagneGas Corporation (Nasdaq: MNGA). Prior to 2007, Ms. Ingargiola held various roles as Budget Director and Investment Analyst in several private companies. Ms. Ingargiola graduated in 1989 from Boston University with a Bachelor’s degree in Business Administration and a concentration in Finance. In 1996, she received her MBA in Health Administration from the University of South Florida. Ms. Ingargiola is qualified to serve as a Chief Financial Officer because of her extensive knowledge corporate governance, regulatory requirements, executive leadership and knowledge of, and experience in, financing and M&A transactions.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND ONE HUNDRED TWENTY FIVE USD BY SHORE THING MEDIA LLC FOR A ONE DAY ALBT AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: MGRX)

***Sponsored by Shore Thing Media, LLC

Mangoceuticals, Inc. logo

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

(Notice the video has almost 10 Mill Views)

_____________________

Hello Everyone,

We have a company back on our radar that we haven’t taken a look at in a few years and they have been up to A LOT since we last brought this one to your attention.

This one was also down big today, making it a solid bounce play to research right now.

This company loves to make big wild double digit swings on a regular basis.

It just dropped double digits but if you are looking at the chart on this one you will see that it’s no big deal.

This is a company that has a lot going on as you can see by all the headline above.

They started off as one trick pony and since their successful IPO that occured over 2 years ago they have been expanding into other wellness markets and now have several irons in the fire.

‍

‍Pull up MGRX immediately.

The growing demand for discreet, online solutions in healthcare has created a ripe environment for MangoRx to expand. Competitors like Hims & Hers and Roman have validated the model, and MangoRx is carving out its niche by emphasizing pharmaceutical-grade treatments. This approach not only sets it apart in terms of safety and credibility but also opens the door for insurance partnerships and broader acceptance in clinical settings.

Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name “Mango” (think “Man Go”).

Created using a special formulation featuring the same active ingredient as in Cialis (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.

Mango is a prescription medication that must be approved by a physician. After an individual has completed an online telehealth visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.

Mangoceuticals is making waves in the men’s health market with its innovative approach and commitment to redefining the standards for ED treatment. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers.

The men’s health sector is ripe with potential, offering attractive opportunities as companies meet the growing demand for male-centric wellness solutions. Recent market research projects a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. A confluence of factors, including a rise in men’s health awareness, a paradigm shift in societal norms that emphasize self-care, and ground-breaking developments in medical technology and research, are just a few of the factors driving the growth in this sector.

The men’s health market encompasses a diverse range of products and services, including pharmaceuticals, dietary supplements, fitness equipment, personal care products, telehealth services, and tailored wellness programs. These offerings cater to various aspects of men’s health, including physical fitness, mental wellness, and nutritional support.

Beyond product offerings, Mangoceuticals understands the importance of education and information in men’s health. MangoRx is dedicated to providing comprehensive knowledge and resources, empowering men to make informed decisions about their well-being. By sharing information confidently and breaking down barriers, Mangoceuticals is destigmatizing the conversation around men’s health.

MangoRx offers a convenient telemedicine platform, allowing men to access their products without leaving their homes. By eliminating the need for in-person doctor visits, MangoRx provides a discreet and accessible solution for men’s health needs. With a streamlined process, users can create an account, complete a telemedicine session, and have their prescribed products delivered to their doorstep.

The MangoRx approach differs from other ED treatments in its commitment to education and refreshing approach to the topic. While the subject matter is serious, MangoRx embraces a fun and confident attitude. By injecting humor into their brand, they aim to empower men on their journey to better health, ensuring that the pursuit of ‘intimate well-being’ is an enjoyable experience.

Mango (Man-Go)

Mango, Mangoceuticals’ flagship product, is a groundbreaking solution designed to address men’s unique concerns. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations.

Mango stands out with its rapid-dissolving mango-flavored tablets, which deliver quicker results by efficiently entering the bloodstream. These sublingual Rapid Dissolving Tablets (RDTs) contain the same active ingredient as Cialis (tadalafil), as well as the MGRX unique blend. By incorporating this combination, Mango offers a tasty, efficient, and powerful solution for men seeking faster relief from the symptoms of ED.

Earlier this month, MGRX announced via Twitter that Mango is now available in Nevada. This expansion marks a significant milestone for Mangoceuticals as they continue to broaden their market reach and offer their cutting-edge men’s health and wellness products to new potential customers.

Mango is now available in 44 states, including Nevada and the District of Columbia.

Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada

Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace

DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into a Master Distribution Agreement (the “Agreement”) to secure the exclusive licensing and distribution rights for Diabetinol® within the United States and Canada.

Diabetinol® is a plant-based nutraceutical clinically supported and patented extract of citrus peel rich in polymethoxylated flavones (PMFs), including nobiletin and tangeretin. Based on clinical studies performed, these compounds have demonstrated significant metabolic effects, particularly in how the body processes and utilizes sugar and fat. Mechanistically, Diabetinol® works by improving insulin sensitivity, enhancing GLUT4-mediated glucose uptake in tissues, suppressing hepatic glucose production, and activating key enzymes involved in lipid metabolism. It also reduces systemic inflammation and oxidative stress—two of the primary biological drivers of insulin resistance and metabolic dysfunction.

Under the agreement, Mangoceuticals will hold the exclusive rights to market and sell Diabetinol® across the United States and Canada, expanding its product portfolio into the $33.66 billion addressable diabetes and metabolic health market.

“Millions of people are left on the sidelines watching others lose weight using drugs they can’t afford,” said Jacob Cohen, Founder and CEO of Mangoceuticals, Inc., who continued, “Diabetinol® is not a direct substitute for those prescription therapies, but the internal studies have concluded that it does offer complementary metabolic benefits in a safe, natural, and more affordable way. By harnessing clinically proven plant-derived ingredients, we’re providing a new option for individuals who cannot access or tolerate GLP-1 medications. Our goal is to help more people take control of their blood sugar and weight – safely, conveniently, and cost-effectively.”

Mangoceuticals’ expansion into metabolic health is timely given the escalating diabetes crisis and the enormous total addressable market for such solutions. In the U.S. alone, over 30 million Americans suffer from type 2 diabetes, and approximately 97.6 million American adults—more than one in three—have prediabetes. Globally, an estimated 537 million adults are currently living with diabetes, and that number is expected to rise to 783 million by 2045. If current trends continue, projections suggest it could exceed 1.3 billion by 2050.

The healthcare burden associated with this is immense. U.S. diabetes-related healthcare costs are already over $400 billion per year. Meanwhile, global spending on weight loss and blood sugar–lowering medications reached $24 billion in 2023 and is projected to surpass $131 billion by 2028. Currently, many people are prescribed metformin yet discontinue second-line therapies due to cost or tolerability. With an estimated 50% of Americans actively trying to lose weight at any given time, the demand for safer, more affordable metabolic health solutions is surging.

We believe that Diabetinol® is well-positioned to fill that gap. As a naturally derived, clinically supported nutraceutical, it offers a compelling option for consumers who either can’t tolerate or access GLP-1 drugs, or who are seeking to support their health with a non-pharmaceutical approach.

Mangoceuticals intends to distribute Diabetinol® in multiple consumer-friendly formats including capsules, a ready-to-drink beverage, quick-release pouches, cookies, and gummies. Each product will be carefully dosed to deliver consistent clinical levels of Diabetinol’s active ingredients. Distribution is expected to include direct-to-consumer online initiatives via our own website and through online retailers, brick and mortar retail outlets, and affiliate marketing channels.

Najla Guthrie, Founder of KGK Synergize and a recognized leader in nutraceutical clinical research, expressed strong support for Diabetinol’s role in addressing metabolic dysfunction, “I believe that Diabetinol® has the potential to revolutionize how we think about supporting metabolic health. Its unique blend of natural citrus-derived compounds has been shown to deliver meaningful improvements in glycemic control, lipid profiles, and blood pressure—offering a safe and clinically validated adjunct to conventional care for those with prediabetes or diabetes,” said Guthrie. She further noted that Diabetinol’s formulation, centered around compounds like nobiletin and tangeretin, has been shown in rigorous clinical trials to improve glucose tolerance and lipid levels without adverse impacts on liver, kidney, or other organ functions and believes that these findings support Diabetinol as a safe, science-backed option to help manage blood sugar and reduce risk factors associated with cardiovascular disease.

Mr. Cohen further added, “Obtaining the exclusive rights to Diabetinol is a major milestone for Mangoceuticals. We are proud to introduce an innovative, science-backed nutraceutical that aligns with our mission of improving lives through safe and accessible wellness solutions. Diabetinol’s arrival could not be more timely, as the world faces a metabolic health epidemic and we have seen that patients are seeking alternatives that are both effective and affordable. We believe Diabetinol® can become an invaluable option for individuals looking to take charge of their metabolic health, and we’re excited to lead that charge.”

In recent years, there has been growing public awareness around the need for cleaner, more natural approaches to health and wellness. Leaders in the national health conversation, including newly appointed United States Secretary of Health and Human Services, Robert F. Kennedy Jr., have emphasized the importance of reducing reliance on synthetic pharmaceuticals in favor of preventive, plant-based solutions, where appropriate. We believe that Diabetinol® reflects this shift—offering a science-backed, naturally derived option for those seeking to support their metabolic health with fewer chemicals and greater transparency.

About Diabetinol® Clinical Studies

In a 3-month pilot study involving participants with impaired glucose metabolism, Diabetinol® was shown to reduce peak postprandial blood glucose by approximately 50 mg/dL following a glucose challenge test. This reduction is considered clinically meaningful, as it eases the burden on pancreatic beta cells and lowers the risk of long-term damage caused by repeated glucose spikes. Diabetinol® helped participants stabilize blood sugar responses after meals, which is essential for preserving insulin function and preventing complications associated with hyperglycemia.

In a 6-month randomized, double-blind, placebo-controlled study of patients with type 2 diabetes or prediabetes who were already on conventional medications, Diabetinol® was shown to significantly improve a range of health markers. Among those taking Diabetinol®, 14.3% reached Hemoglobin A1c (HbA1c) targets (compared to 0% of the placebo group), 33.3% reached LDL cholesterol goals (vs. 15.4% placebo), 20% reached total cholesterol goals (vs. 12.5% placebo), and 83.3% reached systolic blood pressure goals (vs. 60% placebo). Participants also experienced improved glucose tolerance over time, with a slower rise in fasting glucose levels and improved Oral Glucose Tolerance Test (OGTT) profiles—especially in individuals aged 40 to 60.

Mangoceuticals Announces the Launch of “PeachesRx” – a Women’s Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women’s health and wellness brand focused on providing cutting-edge, convenient treatments tailored to women’s unique health needs. These new and innovative women’s health and wellness products will be made available via a secure telemedicine platform located at www.PeachesRx.com.

‍

No alternative text description for this image

PeachesRx will debut with a strong focus on compounded GLP-1 receptor agonists—a class of medications proven to aid weight loss by regulating appetite and glucose metabolism. Recent studies show that approximately 70% of GLP-1 prescriptions for weight loss are written for women, reflecting their dominant role in driving the surge in demand for these medications. By introducing its tailored GLP-1 offerings, PeachesRx aims to meet the unique metabolic needs of women while providing an accessible and affordable telehealth-driven solution.

Market demand for GLP-1 weight loss treatments among women is expanding rapidly. Industry projections estimate that the global GLP-1 market for weight management will exceed $48 billion by 2030, with women comprising the majority of users. Additionally, the global women’s health market was valued at $49.33 billion in 2024 and is projected to reach $68.53 billion by 2030, growing at a 5.1% CAGR. Within the U.S. women’s telehealth market, growth is fueled by increased awareness, the demand for remote care, and the rise of personalized medicine. PeachesRx is well-positioned to capture this market by delivering GLP-1 solutions tailored to women’s health needs, with seamless access through its HIPAA-compliant telemedicine platform.

“The launch of PeachesRx is the natural next step in Mangoceuticals’ expansion as we continue to redefine direct-to-consumer healthcare solutions,” said Jacob Cohen, CEO and Founder of Mangoceuticals, who continued, “We’ve seen the success of our telehealth platform for men, and we believe there is an even greater opportunity in women’s health. As we have seen with MangoRx in the men’s health market, brand trust, accessibility, and innovative product offerings have been key to driving MangoRx’s success. PeachesRx will follow this blueprint, ensuring that women can confidently access clinically proven treatments tailored to their needs.”

Women represent a dominant force in telehealth adoption, with studies showing that over 60% of telehealth users are female. More than ever, women are seeking convenient, personalized healthcare solutions, and Peaches aims to revolutionize access by providing affordable, effective, and medically supervised treatments via its secure, HIPAA-compliant telemedicine platform.

“Women’s healthcare has been underserved for too long. With PeachesRx, we are transforming access by providing seamless, confidential, and medically backed care,” said Amanda Hammer, COO of Mangoceuticals, who continued, “Our goal is to bring the same level of innovation, affordability, and accessibility that has driven our success in men’s wellness.”

Positioned to be a leader in women’s telehealth, PeachesRx combines an intuitive user experience with a commitment to high-quality care, meeting the evolving needs of today’s healthcare consumers. By initially launching with GLP-1 solutions, PeachesRx intends to lay the groundwork for potential future expansion into broader wellness categories, including, but not limited to, sexual health, hair growth, and hormone therapy solutions. The Company plans to grow PeachesRx into a leader in women’s telehealth.

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.

About PeachesRx

PeachesRx is focused on developing a variety of women’s health and wellness products and services via a secure telemedicine platform. To date, the PeachesRx has identified weight management as the initial product category for its initial launch. Interested consumers can use PeachesRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through PeachesRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about PeachesRx’s mission and other products, please visit www.PeachesRx.com.

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) — Mangoceuticals, Inc.(NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men’s wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation.

Dermytol® is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or long-term damage, Dermytol® utilizes a proprietary blend of clinically validated ingredients, including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera. The patented formulation harnesses the melanin-reducing properties of canola extract, providing a safer and more stable alternative to conventional ingredients like hydroquinone and kojic acid.

The efficacy of Dermytol® as a safe and effective skincare treatment was demonstrated in vitro, where it was tested against Kojic acid—a widely used skin lightening agent derived from fungi. At medium and high concentrations, Dermytol® was found to be more effective at reducing melanin production while being significantly less damaging to skin cells than Kojic acid. According to the study, this would make Dermytol® a superior option for individuals seeking a clinically backed solution for hyperpigmentation and overall skin health.

The global skincare market is projected to reach approximately $218 billion by 2029, growing at a compound annual growth rate (CAGR) of 3.61% from 2025 to 2029. Within this expansive market, the plant-based skincare segment is experiencing significant growth. The global plant-based skincare products market, valued at $789.75 million in 2023, is expected to grow to $1.62 billion by 2033, reflecting a robust CAGR of 7.5% over the next decade. This surge is driven by consumer demand for natural, science-backed skincare solutions that offer visible results without compromising skin health.

Consumers are increasingly prioritizing products that promote healthier, more sustainable options, driving the market for non-retinol skincare solutions. Dermytol®️ is poised to meet this demand with its innovative, clinically proven formulations, addressing a significant gap in the market for safe and effective solutions for hyperpigmentation, dark spots, and uneven skin tone

Jacob Cohen, CEO of Mangoceuticals, Inc., expressed enthusiasm for the partnership, stating: “We are thrilled to add Dermytol®️ to our growing portfolio of high-performance wellness products. The demand for effective, natural skincare solutions is on the rise, and this collaboration allows us to bring a scientifically advanced product to market that aligns perfectly with our mission of delivering high-quality health and wellness solutions.”

Peter Polimeneas, CEO of Propre Energie Inc., added: “This agreement is a significant milestone for Dermytol®️ as we expand into new markets with the support of a strong and experienced partner. Mangoceuticals’ expertise in digital marketing and e-commerce, combined with their dedication to quality, makes them the ideal distributor for our brand.”

Through this agreement, Mangoceuticals secures exclusive rights to market, sell, and distribute Dermytol® across North and South America. The product will be available in both patch and cream formulations, offering versatile treatment options for consumers seeking to improve their skin’s radiance and overall health. Mangoceuticals aims to leverage its robust marketing and distribution infrastructure to accelerate Dermytol®’s penetration in key markets.

About Propre Energie, Inc.

Propre Energie Inc. is a Quebec-based company specializing in plant-based, non-retinol skincare solutions under the Dermytol®️ brand. With a focus on research and innovation, Propre Energie is dedicated to developing clinically proven, safe, and effective skincare products for individuals seeking healthier skin.

NEWS


CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

21 hours ago

Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada

Mar 25, 2025

Mangoceuticals Announces the Launch of “PeachesRx” – a Women’s Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

Feb 20, 2025

Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution

Feb 12, 2025

Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

Feb 6, 2025

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Feb 3, 2025

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Dec 19, 2024

Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split

Dec 4, 2024

Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Oct 31, 2024

MangoRx Announces Formation of Strategy and Alternatives Committee

Oct 22, 2024

‍

MANAGEMENT

Photo of Jacob Cohen

JACOB COHEN

Co-Founder and Chief Executive Officer

Jacob Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising, healthcare, IT and financial services. Prior to founding the Company, Mr. Cohen was the co-founder and managing partner of several boutique investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of debt and/or equity and in both private and public markets.

Prior to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc., a manufacturer, wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller of Metiscan, Inc., a publicly traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded the company’s financial audit process and managed its various filings with the SEC.

From 2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelor of Arts in International Economics and Finance from Brandeis University in Waltham, Massachusetts.

Mr. Cohen has served as Chief Executive Officer of the Company since October 2021, as a director from October 2021 to present, and as Chairman from September 2022 to present. Mr. Cohen also currently serves as Chief Executive Officer and as a director of American International Holdings Corp (“American International”), a publicly traded company which is the majority owner and parent to Epiq Scripts, LLC, and which is the former sole owner of the Company, having fully divested its ownership in June 2022, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private investment company, which role he has held since August 2016. Mr. Cohen also serves the Chief Executive Officer of Cohen Enterprises, Inc., a private investment company, which position he has held since November 2013.

Jonathan Arango is a Business Development Executive with more than 10 years of hands-on experience in pharmacy operations and management, business development, team management, and strategic relationship development. He has a history of driving significant revenue growth for companies in multiple sectors. Mr. Arango participates in numerous ambitious ventures, spanning multiple industries such as e-commerce, medical & health, restaurants, and cryptocurrency.

Photo of Jonathan Arango

JONATHAN ARANGO

Co-Founder and President

Mr. Arango has served as the Co-Founder, President and Director of the Company since October 2021. Prior to his appointment to the Company, Mr. Arango served as Chief Operating Officer of Murphy Rx LLC, a retail and specialty pharmacy based out of Murphy, Texas, which he previously owned, from June 2020 to March 2022. Prior to owning a pharmacy, Mr. Arango founded and served as CEO of Golden Heights Medical Consulting, a healthcare marketing agency that specialized in customer acquisition and medical ancillary services from February 2017 to January 2019. He also served as an independent contractor providing marketing and sales services from April 2015 to February 2017.

Before entering the healthcare industry, Mr. Arango ran an independent marketing and sales agency from 2013 to 2018 (A&J Marketing). A&J Marketing was contracted by multiple companies spanning different industries to generate and substantially scale revenue in multiple sectors. Industries included were Home Improvement, Oil & Gas, Health & Wellness, Professional Development, and E-commerce.

Photo of Amanda Hammer

AMANDA HAMMER

Chief Operating Officer

Amanda Hammer has been a member of the MangoRx team since late 2022 and has been instrumental in launching and optimizing MangoRx’s eCommerce platform. She is a proven leader with a track record of success having recently completed a 4-year tenure at D Magazine Partners, a Dallas based multimedia company, where she held roles leading Audience Development, Brand, and Digital Operations, quickly rising to become the company’s first named Chief Operations Officer. Prior to that, Amanda worked in private equity consulting and assisting newly acquired business verticals with optimizing sales and marketing processes, improving subscription retention, and training new talent to enhance productivity and maximize revenue streams.

Amanda obtained dual Bachelor of Arts degrees—in Graphic Design and Communication Studies—from the University of Iowa. She has also obtained a Negotiation and Leadership Certificate from Harvard Law School and is a recent graduate of the Texas Women’s Foundation Leadership Institute.

Photo of Eugene M. Johnston

EUGENE M. JOHNSTON

Chief Financial Officer

Mr. Johnston has served as Chief Financial Officer of the Company since October 2022. Since February 2015, Mr. Johnston has served as Audit Manager for Greentree Financial Group, Inc., an accounting and auditing firm. From August 1999 to September 2014, Mr. Johnston served as Chief Executive Officer of Peoplesway.com, Inc., a skincare and nutritional products company, and from August 1999 to present, Mr. Johnston has served as a member of the Board of Directors of Peoplesway.com, Inc. From January 1999 to July 1999, Mr. Johnston served as Chief Executive Officer of RMC Group, Inc., a skincare and nutritional products company. Prior to that, from April 1987 to January 1989, Mr. Johnston served as Vice President of Sales Administration at WeCare Distributors, Inc., a skincare and nutritional products company.

Mr. Johnston received a Bachelor’s in Science in Business Administration from the University of North Carolina Charlotte.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND THREE HUNDRED FIFTY USD BY SHORE THING MEDIA LLC FOR A ONE DAY MGRX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

ATLX

***Sponsored by Sideways Frequency, LLC

ATLX

‍

CHECK OUT THE INVESTOR PRESENTATION HERE ‍

_________________________

Hello Everyone,

We have another past winner back in the cross hairs for tomorrow’s session.

The last time we looked at it this one was sitting around 5.30 and ran to 6.50 over the next 2 weeks.

Since then it has pulled back a bit with the market but it is still seeing strong interest every day in anticipation of production on the horizon.

Focused on moving from exploration to profitability; Atlas Lithium Corporation (NASDAQ: ATLX) is a U.S.-based mineral exploration company with the largest size and breadth of exploration projects for strategic minerals in Brazil, a premier mineral jurisdiction.

ATLX intends to be a leader in the provisioning of minerals essential to the transformation of the global economy from fossil fuels to electrification, a process which is expected to take decades.

The company’s properties encompass approximately 539 km2 for lithium, as well as mineral rights for nickel, rare earths, titanium and graphite. Atlas Lithium also owns 32% of Atlas Critical Minerals Corporation.

Company Highlights

Over the last several years, Atlas Lithium has assembled Brazil’s largest portfolio of lithium mineral rights among publicly listed companies.

ATLX holds three key projects that span the major lithium-mineralized zones in LV:

  1. The Neves Project in southern LV, Atlas Lithium’s flagship development, which has recently been permitted and is advancing towards production;

  2. The Salinas Project in northern LV, spanning 2,070 acres with natural spodumene outcrops, and is located 4.7 miles from Latin Resources Ltd., and with potential for spodumene deposits;

  3. The Clear Project in central LV, which encompasses 470 acres, is situated 3.8 miles from Sigma Lithium’s (NASDAQ: SGML) Grota do Cirilo mine. There is also potential for spodumene deposits. Sigma Lithium has a market cap of roughly $1.2B! (Note: ATLX’s lithium processing manager James Schloffer had a key role at Sigma!)

Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production

Boca Raton, Florida–(Newsfile Corp. – March 10, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium development company, announces the successful arrival of its modular Dense Media Separation (DMS) lithium processing plant at the Port of Santos, Brazil. This pivotal achievement underscores the Company’s progress toward becoming a key lithium producer in Brazil’s emerging Lithium Valley.

The components of Atlas Lithium’s lithium processing plant were carried by the cargo vessel Irene’s Wisdom (IMO: 9953391) which arrived at the Port of Santos on March 7, 2025, delivering 141 containers and 10 bulk components. Fully owned and paid for by Atlas Lithium, this newly manufactured facility departed from the Port of Durban, South Africa, on February 2, 2025, following months of careful planning and preparation. Two additional containers, containing spare parts, are scheduled to arrive in the near future.

“This marks a transformative milestone for Atlas Lithium as we advance toward becoming a global supplier in the lithium market,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “With operational permits secured and our modern lithium processing facility now in Brazil, we have overcome two of the most significant hurdles on our journey to production.”

Cutting-Edge Modular Plant Design

Atlas Lithium’s lithium processing plant incorporates advanced design elements and sustainable technology that set a new benchmark for lithium processing:

  • Compact, Modular Design: Allows streamlined transportation, installation, and commissioning, reducing time to production.
  • Reduced Environmental Footprint: Optimized physical layout minimizes environmental impact while maintaining high operational efficiency.
  • Advanced Water Conservation: Internal recycling systems with lower water consumption compared to traditional plants.
  • Sustainable Tailings Management: Dry-stacking technology eliminates the need for tailings dams, promoting greater environmental sustainability.

Strategic Progress Toward Production

The Neves Project, Atlas Lithium’s flagship operation, received its operational permit from the state of Minas Gerais in October 2024. The project is positioned to initially produce up to 150,000 tonnes per year of battery-grade spodumene concentrate, a critical raw material for lithium-ion batteries.

Atlas Lithium’s operations will benefit from Brazil’s Lithium Valley’s strategic advantages, including expected lower production costs as compared to suppliers from Australia and other regions.

Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure

Boca Raton, Florida–(Newsfile Corp. – March 5, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium exploration and development company, is pleased to highlight its current 32.2% stake in Atlas Critical Minerals Corporation. This ownership positions Atlas Lithium at the forefront of Brazil’s critical minerals sector, providing exposure to rare earth elements, titanium, graphite, uranium, and other sought-after minerals.

“Global demand for critical minerals has never been more urgent,” said Marc Fogassa, CEO and Chairman of Atlas Lithium. “Recent geopolitical developments have underscored the vital importance of critical minerals for economic and national security. Atlas Lithium is strategically positioned to play a key role in this increasingly important sector.”

Rare Earths: Essential for Defense, Energy, and High-Tech Applications

Rare earth elements are indispensable components in manufacturing permanent magnets used in electric vehicle (EV) motors, wind turbines, and defense systems. With Chinacurrently controlling over 60% of global rare earth mining and 85% of refining capacity, recent export restrictions have underscored the need for alternative supply sources.

Atlas Critical Minerals’ extensive rare earth portfolio spans approximately 54,000 hectares (~133,000 acres) across 33 mineral rights in the states of Goiás and Minas Gerais in Brazil. These areas have demonstrated promising mineralization, with soil samples revealing rare earth oxide (TREO) concentrations as high as 15,000 ppm and titanium dioxide concentrations up to 20%.

Graphite: A Cornerstone of Battery Technology

Graphite is a critical component for lithium-ion batteries, which power electric vehicles and renewable energy storage systems. As global EV adoption accelerates, demand for natural graphite has surged, making the development of new sources outside of traditional suppliers like China a strategic imperative. Atlas Critical Minerals is actively evaluating areas in Brazil with known graphite formations, with the goal of contributing to the global supply of this essential material.

Uranium: Fueling the Energy Transition

Uranium is experiencing renewed global demand as nations prioritize energy security, geopolitical stability, and decarbonization. With nuclear power offering a reliable, low-carbon energy source, uranium has become integral to the energy transition. Atlas Critical Minerals is focused in certain areas in Brazil with promising geological characteristics for uranium. In Brazil, uranium is strictly regulated and exploration requires special permitting, which is not guaranteed. Nevertheless, this sector is expected to continue to grow substantially as Brazil activates its third nuclear reactor for electricity generation and as global demand continues to rise.

A Diversified Strategy for a Changing World

Atlas Lithium’s ownership stake in Atlas Critical Minerals strategically complements its flagship Neves Project in Brazil’s Lithium Valley. This diversified approach provides shareholders with exposure to multiple critical minerals essential for the global energy transition and advanced manufacturing sectors.

“In today’s environment of persistent geopolitical tensions, the need for reliable, diversified critical mineral supply chains has never been clearer,” added Fogassa. “While our immediate focus is to bring our lithium production online and generate profits, Atlas Lithium’s long-term strategy is to establish itself as a leader in the global critical minerals space.”

‍

Strategic Partnership with Global Industrial Giant

In a transformative development, Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries. In March 2024, Mitsui demonstrated its confidence in Atlas Lithium’s potential by making a substantial US$30 million strategic investment at a 10% premium to market price. The partnership includes a significant offtake agreement lithium concentrate from Atlas Lithium’s Neves Project. Notably, Mitsui’s largest shareholder is Warren Buffett’s Berkshire Hathaway, adding another layer of institutional validation to Atlas Lithium’s business model.

Mine

‍

Within the global lithium industry, Brazil’s LV has emerged as a premier hard-rock lithium jurisdiction.

Brazil’s advantages include year-round mining operations, lower labor costs, and a supportive government. The country’s lithium industry outperforms Australian producers on costs; Pilbara Mineral’s US$370M acquisition of a Brazilian lithium explorer in August 2024 highlights the region’s importance.


“Investments in lithium production in Minas Gerais are projected to range from $3.9 billion to $5.8 billion by 2030,” according to João Paulo Braga, CEO of the state investment promotion agency, Invest Minas.

Few countries besides Brazil have such an advantageous position to attract investment, as other Latin American nations face uncertainties and political risks.

ATLX’s Minas Gerais Lithium Project is its largest endeavor and consists of 85 mineral rights totaling approximately 468 km2 which include seven main clusters of prospective mineralization: Neves (currently being explored by drilling campaign and referred to as the “Neves Project”), Coronel Murta, Eastern Properties, Itinga, Salinas, Santa Clara, and Tesouras.

Several of the company’s mineral rights are located adjacent to or near mineral rights that belong to a large publicly traded competitor company which has demonstrated through extensive drilling the presence of lithium deposits totaling over 100 million tons, according to its publicly available filings!

This is a Highly Attractive Location:

◼ Resource Potential to Support Large Scale Operations
✓ The Brazilian Geological Service (CPRM) suggested that the region has at least 45 lithium deposits
✓ Adjacent to operational lithium mines in the region such as Sigma Lithium and CBL

◼ Licensing Fast Track to Speed up Project Execution – Atlas with Permits in Place
✓ Minas Gerais government created a fast-track process, under the InvestMinas Program, to facilitate project development and allow for licensing to be issued quickly
✓ Mining friendly jurisdiction: 300+ operating mines in the state of Minas Gerais

◼ Favorable Infrastructure
✓ Access to abundant renewable & clean energy sources and highway roads directly connected to intercontinental ports to supply main markets

Map

Recent exploration activities at both the company’s Salinas and the Clear Projects have yielded significant progress, and such development bodes well for ATLX’s strategy of securing as many high-quality deposit areas within LV as feasible.

A Big Neighbor

Atlas Lithium’s strategic holdings of 85 mineral rights across 468 km2 in Minas Gerais position it as the emerging force in Brazil’s Lithium Valley, with several properties adjacent to Sigma Lithium Corporation, the region’s established producer. Sigma’s current market capitalization of approximately $1.2 billion—approximately twelve times that of Atlas Lithium—demonstrates the extraordinary value potential in the region. As Atlas Lithium follows a similar development path in the same proven lithium district the company represents a compelling growth opportunity at its current market valuation. The success of Sigma Lithium in establishing large-scale lithium operations provides a clear blueprint for Atlas Lithium’s development trajectory in this world-class mining jurisdiction.

NEWS


Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production

Mar 10, 2025

Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure

Mar 5, 2025

Feb 10, 2025


Atlas Lithium to Present at Fastmarkets Battery Raw Materials Shanghai 2025 Conference


Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production

‍

Atlas Lithium’s Plant Is Now En Route to Brazil – Marking Major Milestone Towards Production

Feb 3, 2025

Atlas Lithium’s Processing Plant Prepares for Shipment to Brazil

Jan 21, 2025

Atlas Lithium Accelerates Production Readiness with Key Executive Appointments

Dec 30, 2024

Atlas Lithium Outlines Regional Growth Strategy

Nov 25, 2024

Atlas Lithium’s Neves Project Is Now Permitted

Oct 28, 2024

Atlas Lithium Advances Its Salinas Project

Oct 7, 2024

Atlas Lithium Progresses Towards Key Permitting

Sep 23, 2024

Atlas Lithium’s Progress: Processing Plant Readies For Shipment To Site

Aug 28, 2024

Atlas Lithium Recognized for Its Plant Design

Aug 27, 2024

Atlas Lithium’s Modular Lithium Processing Plant Readies for Brazil

Aug 22, 2024

All Eyes On Atlas Lithium As The US Assistant Secretary Of State For Energy Resources Visits The Company’s Headquarters In Brazil

Jul 26, 2024

Atlas Lithium Strengthens Position In Global Market With Brazilian Mineral Rights Expansion

Jun 24, 2024

Atlas Lithium Doubles the Size of Its Lithium Exploration Footprint in Brazil; Provides Exploration Update

Jun 17, 2024

Atlas Lithium to Co-host the Inaugural Brazil Lithium Summit

Jun 3, 2024

Atlas Lithium (NASDAQ: ATLX) Positions Itself To Meet Soaring Global Lithium Demand With Strategic Investments From Global Partners

May 30, 2024

Atlas Lithium (NASDAQ: ATLX) Reaches Final Fabrication And Trial Assembly Stage For Its Modular Lithium Processing Plant

May 14, 2024

Atlas Lithium’s Modular Processing Plant Enters Final Fabrication and Trial Assembly Stage

May 7, 2024

Atlas Lithium (NASDAQ: ATLX) Secures Partnerships With Suppliers To Tesla, BYD And Secures Funding From Mitsui & Co. To Fuel Growth

Apr 12, 2024

Atlas Lithium (NASDAQ: ATLX) Secures Game-Changing $30,000,000 Strategic Investment From Mitsui & Co.

Apr 2, 2024

MANAGEMENT

Marc Fogassa

Chairman & Chief Executive Officer

Marc Fogassa has been a director and our Chairman and Chief Executive Officer since 2012. He has extensive experience in venture capital and public company chief executive management. He has served on boards of directors of multiple private companies in various industries and has been invited to speak about investment issues, particularly as related to Brazil. Mr. Fogassa double majored at the Massachusetts Institute of Technology (M.I.T.), graduating with two Bachelor of Science degrees in 1990. He later graduated from the Harvard Medical School with a Doctor of Medicine degree in 1995 and also from the Harvard Business School with a Master of Business Administration degree in 1999 with Second-Year Honors. At Harvard Business School, he was Co-President of the Venture Capital and Private Equity Club. Mr. Fogassa was born in Brazil and is fluent in Portuguese and English. Mr. Fogassa is also the Chairman and Chief Executive Officer of Jupiter Gold Corporation and Chairman and Chief Executive Officer of Apollo Resources Corporation, two companies in which we own equity positions.

Tiago Miranda

CFO & Treasurer

Tiago Miranda is our Chief Financial Officer, Principal Accounting Officer, and Treasurer. From February 2024 until July 2024, Mr. Miranda was the Chief Financial Officer of Apollo Resources Corporation, a private company and a subsidiary of Atlas Lithium. In such capacity, Mr. Miranda managed all of Apollo Resources’ financial and administrative related processes, including treasury, accounting, tax, and financial planning and budgeting.

Previously, from May 2020 to December 2023, Mr. Miranda was the senior financial officer for the Brazilian operations of Horizonte Minerals Plc., a British publicly listed company with two nickel projects in Brazil. During his tenure, he successfully contributed to securing project financing of US$713 million for a ferronickel project and an additional $300 million Brazilian real credit facility with Banco da Amazônia. Between November 2019 to April 2020, Mr. Miranda held the position of Financial Controller for the Brazilian operations at Equinox Gold, a Canadian publicly listed gold producer.

From March 2008 to October 2019, Mr. Miranda served as the Controller of Ferrous Resources Ltd., an iron producer partially owned by Icahn Enterprises, a NYSE-listed company. He actively contributed to the development of company projects from exploration through construction and operation and was also heavily involved in Ferrous Resources’ US$550 million sale to Vale S/A, the largest Brazilian mining company.

From September 2005 to March 2008, Mr. Miranda was an auditor with Deloitte Touche Tohmatsu in Brazil. He has an undergraduate degree in Business Administration and Accounting, and a Master of Business Administration, both from IBMEC in Brazil. Mr. Miranda is fluent in Portuguese and English.

Eduardo Queiroz

Project Management Officer (PMO) & Vice President of Engineering

Eduardo Queiroz has served as Project Management Officer and Vice President of Engineering at Atlas Lithium since December 2024. He brings over 20 years of expertise in managing large-scale and complex mining projects, most recently as General Manager of Planning and Management at Bamin, a unit of Eurasian Resources Group. During his tenure at Bamin, he successfully led the strategic planning of several projects exceeding US$3 billion in value, including an integrated iron ore mining project that encompassed mining operations, processing plant, railway, and ocean port facilities.

Mr. Queiroz’s comprehensive experience includes engineering oversight, environmental compliance, risk management, and the implementation of cost-efficient operational strategies. His expertise in project implementation and management of Brazilian mining projects makes him instrumental in driving Atlas Lithium’s Neves Project toward revenue generation. He holds an MBA in Project Management from Fundação Getúlio Vargas and a degree in Civil Engineering from the Universidade Federal de Ouro Preto.

Igor Tkachenko

Vice President, Corporate Strategy

Igor Tkachenko has been our Vice President of Corporate Strategy since 2023. Igor Tkachenko, a Ukrainian-American and a US-trained physician, has served as a strategic advisor to us since 2021, lending his leadership talents and private sector experience to further the company’s mission to become a leading hard-rock lithium provider for the green energy transition. In 2022, Mr. Tkachenko began consulting for us as our Director of Strategic Development, overseeing the rapid expansion of our investor relations efforts. He participated in the design and execution of our organizational growth strategy that led to our successful up-listing to Nasdaq in January 2023. On the heels of this major milestone, Mr. Tkachenko transitioned from his academic role as a Clinical Assistant Professor to take on an executive position at Atlas Lithium and began serving as our Vice President of Corporate Strategy in 2023. His education includes a Bachelor of Science (Summa Cum Laude) and a Doctor of Medicine degrees.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY ATLX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

DVS

***Sponsored by LFG Equities Corp & Dolly Varden Silver Corp.

CHECK OUT THE INVESTOR PRESENTATION HERE

Hello Everyone,

We are kicking the week off with a highly unique situation that doesn’t come across our desk too often.

This next one was recently trading on the “QX” exchange which was already the premier exchange on the OTC.

However, they were able to accomplish something that many companies talk about but few are able execute on.

Management was able to up-list this company from the QX to the NYSE American exchange.

Today (Monday) is the first day that this one will be trading under the new symbol, DVS.

There will be a lot of eyes on this one this morning after the uplisting so we want you to research it immediately.

The company has some big names behind it as you can see. Any time I see the name Eric Sprott involved I take notice. If you don’t know who he is then I advise you to look him up. Sprott is behind some of the “smartest” money involved in North American mining and knows the sector and the properties as well as anyone.

Dolly Varden Silver Corporation is a mineral exploration company focused on advancing its 100% held Kitsault Valley Project (which combines the Dolly Varden Project and the Homestake Ridge Project) located in the Golden Triangle of British Columbia, Canada, 25kms by road to tide water. The 163 sq. km. project hosts the high-grade silver and gold resources of Dolly Varden and Homestake Ridge along with the past producing Dolly Varden and Torbrit silver mines. It is considered to be prospective for hosting further precious metal deposits, being on the same structural and stratigraphic belts that host numerous other, on-trend, high-grade deposits, such as Eskay Creek and Brucejack. The Kitsault Valley Project also contains the Big Bulk property which is prospective for porphyry and skarn style copper and gold mineralization, similar to other such deposits in the region (Red Mountain, KSM, Red Chris).

Dolly Varden Silver is advancing one of the largest high-grade, undeveloped precious metal assets in B.C.

The locals in this area have actually given it a name: the Golden Triangle. Over 150 mines have operated in this area since prospectors first arrived at the end of the 19th century.

The Golden Triangle is famous for its vast deposits of gold and copper, as well as other high-demand minerals such as silver, nickel, and zinc. This area is also known to be mining-friendly and to have much of the necessary infrastructure already in place.

Only an estimated 0.0006% of the region around the Golden Triangle has been mined according to the government of British Columbia.

The Golden Triangle includes the largest undeveloped Cu-Au porphyry deposit, the highest-grade recently opened underground gold mine, and the most precious metal-rich VMS ore body in the world.

This region is prime for more Mergers & Acquisitions as you can see:

‍

Dolly Varden Silver Announces NYSE American Listing Approval

Vancouver, British Columbia – April 15, 2025 – Dolly Varden Silver Corporation (TSXV: DV) (OTCQX: DOLLF) (the “Company” or “Dolly Varden”) announces that its common shares have been approved for listing on the NYSE American, LLC (the “NYSE American”). The Company’s common shares are expected to begin trading on the NYSE American under its new symbol “DVS” on April 21, 2025 or as soon thereafter as is permissible pursuant to applicable exchange rules and securities laws. The common shares are expected to continue to trade on the OTCQX until the close of market on or around April 17, 2025. Current stockholders of the Company do not need to take any action prior to the Company’s expected listing on the NYSE American.

Shawn Khunkhun, President and CEO, stated, “By listing on the NYSE American, we are gaining access to the world’s largest and most liquid equity markets, which we believe will create significant value for our shareholders. This move will make it much easier for both institutional and retail investors in the U.S. to invest in Dolly Varden through platforms they already use. With our advanced past-producing and exploration projects, we believe Dolly Varden presents a strong opportunity for American investors seeking exposure to high-grade silver in a secure jurisdiction.”

Silver is both a precious metal and an industrial metal. As the world goes more green and tech-heavy, silver demand rises

‍Right now silver is historically undervalued compared to gold.

People often reference the Gold/Silver Ratio (how many ounces of silver it takes to buy an ounce of gold). Historically, this hovered around 40–60. In recent years, it’s been over 80–90 at times, suggesting silver is “cheap” relative to gold.

Some investors interpret that as a chance to “catch up.”

Unlike gold (mostly a store of value), silver has real-world demand in industries like:

  • Solar panels (photovoltaics)
  • Electric vehicles (conductive wiring)
  • Electronics (smartphones, tablets)
  • Medical uses (antibacterial properties)

_______________

They recently consolidated the shares and today is the first day of trading on the NYSE American for DVS. We expect to have a lot to update you on later in the session so make sure you have DVS sitting at the top of your screen.

NEWS

April 17, 2025

Dolly Varden Silver Engages Marketing Services

2 days ago
Dolly Varden Silver Announces NYSE American Listing Approval

Dolly Varden Silver Engages ICP Securities Inc. for Automated Market Making Services

Apr 4, 2025

Dolly Varden Silver Announces Application to List on the NYSE American and Share Consolidation

Apr 2, 2025

Dolly Varden Silver Announces Grant of RSU and Stock Options

Feb 28, 2025

Dolly Varden Silver Step-out Intersects 21.55 g/t Au and 27 g/t Ag over 8.72m, including 91.1 g/t Au and 114 g/t Ag over 0.51m at Homestake Silver Deposit

Feb 3, 2025

Dolly Varden Silver’s 120 Meter Step-Out at the Wolf Vein Intersects 379 g/t Silver over 21.69 Meters, Including: 1,804 g/t Silver over 1.67 Meters

Jan 7, 2025

Dolly Varden Silver Intersects 12.23 g/t Au and 84 g/t Ag over 34.93m, 29.24 g/t Au and 16.94 g/t Ag over 13.94m at the Homestake Silver Deposit

Nov 4, 2024

Dolly Varden Silver Intersects 654 g/t Silver over 21.48 meters at Wolf Vein and Expands 2024 Drill Program

Sep 9, 2024

Dolly Varden Silver’s Step-out Drilling Intersects 606 g/t Silver over 16.38 meters at Wolf Vein

Aug 19, 2024

Dolly Varden Silver’s Step-Out Intersects 1,091 g/t Silver over 9.38 Meters at Wolf Vein

Aug 12, 2024

Dolly Varden Silver’s Step-out Drilling Intersects 606 g/t Silver over 16.38 meters at Wolf Vein

Aug 19, 2024

Dolly Varden Silver’s Step-Out Intersects 1,091 g/t Silver over 9.38 Meters at Wolf Vein

Aug 12, 2024

Dolly Varden Silver Intersects 978 g/t Ag over 5.00 meters, Including 3,670 g/t Ag over 0.79m at Moose Vein

Jun 19, 2024

Dolly Varden Silver Commences 2024 Drilling Program with Discovery-Focused Exploration Targets

May 21, 2024

CEO.CA’s Inside the Boardroom: Latest Updates From Dolly Varden Silver and Argentina Lithium & Energy

Apr 29, 2024

MANAGEMENT TEAM

Shawn Khunkhun

CEO, PRESIDENT & DIRECTOR

Mr. Shawn Khunkhun has over 20 years of expertise in capital markets and mineral exploration, with a strong focus on creating shareholder value. Over his career, he has facilitated over $2 billion in capital raises, playing a transformative role in advancing exploration, development, and production companies. In his leadership roles as CEO, Director, and Executive Chairman, Mr. Khunkhun has been instrumental in elevating the profiles of undervalued companies and driving strategic growth.

Mr. Khunkhun’s success in incubating and scaling companies through capital raises, acquisitions, and spinouts is powered by an extensive network of high-net-worth investors, private equity, institutional investors, analysts, brokers, and bankers.

Mr. Khunkhun currently serves as a Director of Goldshore Resources and Gladiator Metals and as Director & Executive Chairman of Strike Point Gold. Additionally, he advises West Red Lake Gold Mines, Nations Royalty, and NexGold and is the Founder of Argenta Silver.

Robert Van Egmond, V.P.Geo.

VICE-PRESIDENT EXPLORATION, QUALIFIED PERSON

Rob van Egmond is a professional geologist with over 30 years of experience in the international mining industry. His career encompasses a wide spectrum of experiences ranging from grass roots project generation to pre-feasibility level resource development and mine geology. He has worked with major mining companies (Cominco, BHP, Kennecott) and junior explorers (Orex Minerals, Platinum Group Metals, Candente, Northern Dynasty, Keewatin) gaining experience in a wide variety of commodities and deposit types spanning locations North and South America as well as Africa. Included in his experience are several years of exploration and pre-development work in the Iskut River/Golden Triangle area with Cominco. Mr. van Egmond holds a Bachelor of Science in Geology from the University of British Columbia and is a registered professional geoscientist in good standing with Engineers and Geoscientists British Columbia (EGBC).

Ann Fehr

CHIEF FINANCIAL OFFICER

Ms. Fehr CPA, CGA received her accounting designation in 1996 and has more than 25 years of business experience with management, complex transactions, corporate finance, financial reporting, governance, and regulatory compliance. She has held part-time officer positions for venture listed companies since 2009 and is the founder and president of Fehr & Associates, which provides consulting services to a number of mineral exploration company clients. Ms. Fehr and the accounting team at Fehr & Associates are responsible for financial management, reporting, administration and corporate governance.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND TWO HUNDRED FIFTY USD BY LFG EQUITIES CORP FOR A ONE DAY DVS AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: LRHC) Profile

***Sponsored by Shore Thing Media, LLC

____________________

CHECK OUT THE INVESTOR PRESENTATION HERE

Hello Everyone,

We have another past winner back on our radar for tomorrow’s session. Once upon a time back in 2023 this one was our biggest percentage gainer fo the entire year. A lot has happened since then .

Pull up LRHC right away and start your research. .

‍LRHC was established in 2004 as a comprehensive real estate services platform that seamlessly integrates residential brokerage, mortgage, title, and insurance services, bolstered by a cutting-edge educational support system.

The company boasts a distinctive brokerage model that places the agent at the center, providing them with a 100% commission structure.

Their strategic focus is to drive substantial growth through expansion, seizing the opportunities presented by the evolving trends in the agency model within the real estate industry.

La Rosa Realty’s core operations are primarily within the vast U.S. residential real estate market, which according to Zillow Research, reached a staggering $43.4 trillion in 2021. This marked a remarkable increase of $6.9 trillion since 2020 and more than doubled the levels seen a decade ago.

La Rosa Holdings’ serves as the holding company for a suite of agent-centric, technology-integrated, cloud-based, multi-service real estate companies.

The principal entity, La Rosa Realty, LLC, has earned its place in the “Top 75 Residential Real Estate Firms in the United States” as recognized by the National Association of Realtors (NAR), the leading trade association in the U.S. real estate industry.

The brainchild of the operation is CEO, Mr. Joseph La Rosa, a successful real estate developer, business and life coach, author, podcaster, and public speaker. The business is deeply rooted in his transformative philosophies of family, passion, and growth. Mr. La Rosa’s book, “Do It Now!“, serves as a roadmap to personal success and well-being, inspiring a community of successful realtors who have played a significant role in the business’s growth.

In addition to offering face-to-face residential and commercial real estate brokerage services to the public, the company strategically cross-sells technology-based products and services.

The business is structured around providing services to its agents and the public, encompassing residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, as well as property management.

The primary real estate brokerage operates under the name La Rosa Realty, complemented by a smaller presence under the licensed trade name Better Homes Realty.

The company has established five corporate real estate brokerage offices under the La Rosa Realty brand in Florida, along with 28 franchised real estate brokerage offices in six U.S. states and Puerto Rico.

Additionally, they have expanded globally with an international franchised office in Peru. These real estate offices, both corporate and franchised, are collectively staffed by over 2,380 licensed real estate brokers and sales associates.

La Rosa Holdings Corp. Reports 119% Year-Over-Year Increase in Revenue to $69.4 Million for Fiscal 2024; Surpassed Initial Revenue Guidance by Approximately $4.4 Million

Revenue for the Fourth Quarter of 2024 Increased 55% Year-Over-Year to $17.7 Million

Gross Profit Increased 110% Year-Over-Year to $6.0 Million in 2024

CELEBRATION, Fla., April 16, 2025 (GLOBE NEWSWIRE) — La Rosa Holdings Corp.(NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech company, today provided a business update and reported financial results for the year ended December 31, 2024.

Key Financial Highlights

  • Total revenue increased 119% year-over-year to $69.4 million for the year ended December 31, 2024 from $31.8 million for the year ended December 31, 2023
  • Residential real estate services revenue increased $36.6 million to $57.0 million, or 179%, for the year ended December 31, 2024 from $20.5 million for the year ended December 31, 2023
  • Property management revenue increased by approximately $1.4 million to $11.1 million, or 15%, for the year ended December 31, 2024 from $9.7 million for the year ended December 31, 2023
  • Real Estate Brokerage Services (Commercial) revenue increased by approximately $212 thousand to $328 thousand, or approx. 183% for the year ended December 31, 2024from $116 thousand for the year ended December 31, 2023
  • Gross profit increased by approximately $3.1 million, or 110%, year-over-year, to $6.0 million for the year ended December 31, 2024 from $2.8 million for the year ended December 31, 2023.

Joe La Rosa, CEO of La Rosa, commented, “We are pleased to report a 119% increase in revenue for 2024 compared to 2023, and a 55% increase in Q4 2024 year-over-year compared to the same period in 2023. Gross profit also increased 110% to $6.0 million in 2024, driven by strategic acquisitions of real estate brokerage franchisees and growth in our agent network, which now exceeds 2,500 agents. Our scalable, agent-first brokerage model continues to attract top talent by offering flexible compensation options, including a revenue share program, a 100% commission structure with low fees, and additional income through ancillary services and technology solutions.

“We recently started expanding internationally with engagement of an area developer in Spain, unlocking new revenue opportunities and strengthening our global presence. In addition, we introduced LR Agent Advance, a new program that provides our agents with upfront access to pending commissions, supporting their growth while generating an additional recurring revenue stream for the Company.”

Mr. La Rosa continued, “Importantly, Nasdaq has granted us a 180-day extension to comply with the minimum bid price rule, giving us the necessary time to execute our strategic initiatives. We are on track to close our previously announced acquisition of a real estate brokerage firm, which generated $19 million in revenue in 2023 and, if consummated, is expected to bring a network of around 945 agents across multiple states. Significantly, our revenue forecast for 2025 revenue for $100 Million remains intact.

“Looking ahead, we are focused on achieving profitability in 2025 by expanding into new markets, acquiring additional brokerage firms, growing our agent base, and leveraging technology to drive operational efficiencies. We are confident in our strategy to deliver sustainable growth and maximize shareholder value,” concluded Mr. La Rosa.

The closings of the acquisitions mentioned in this press release are subject to, and contingent upon, the parties entering into their respective definitive agreements. There can be no assurances that these acquisitions will be consummated.

Financial Results

Total revenue for the year ended December 31, 2024, was $69.4 million compared to $31.8 million for the year ended December 31, 2023. Residential real estate services revenue increased by $36.6 million to $57.0 million, or 179%, in the year ended December 31, 2024, from $20.5 million for the year ended December 31, 2023. The increase was driven by $9.8 million of revenue from the eight (8) acquisitions completed during fiscal year 2024, in addition the increase was due to a full year of income from the six (6) acquired companies in 2023. Selling, general and administrative costs, excluding stock-based compensation, for the year ended December 31, 2024, were approximately $11.6 million, compared to $4.8 million for the year ended December 31, 2023. Net loss was $15.9 million, or $(0.79) basic and diluted loss per share, for the year ended December 31, 2024, compared to net loss of $9.3 million, or $(1.27) basic and diluted loss per share, for the year ended December 31, 2023.

INVESTMENT HIGHLIGHTS

  • 2,400+ agents worldwide
  • 35 offices worldwide
  • Became a top 75 residential real estate company in the U.S. in 2016

Future Opportunity

  • Offer additional services such as mortgage, title, homeowner’s insurance
  • Organic growth and expansion to further locations in the U.S. and internationally
  • Create or acquire additional proprietary technologies

Unique Business Model

  • Services include: Residential & Commercial real estate brokerages, franchising, real estate education & coaching, property management
  • Agent centric model
  • Proprietary technology for training and marketing

Financial Strength

  • History of profitability
  • Solid balance sheet
  • Strongly positioned to drive near-term and long-term shareholder value

La Rosa Holdings Corp. Strengthens Balance Sheet by Redeeming and Extinguishing a Large Portion of Outstanding Warrants

PUBLISHED

JAN 28, 2025 8:30AM EST

Celebration, FL, Jan. 28, 2025 (GLOBE NEWSWIRE) — La Rosa Holdings Corp.(NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for six agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that it has fully redeemed and extinguished all of its outstanding warrants (the “Warrants”) previously issued to an institutional accredited investor (the “Holder”). These Warrants, which were exercisable for 2,446,634 shares of common stock of the Company, have now been terminated in their entirety and are no longer exercisable, in accordance with the terms of the Warrant Redemption and Cancellation Agreement (the “Redemption Agreement”) signed by the parties on January 22, 2025.

The Company initially issued these Warrants under the securities purchase agreements dated April 1, 2024, and July 16, 2024, as previously disclosed in the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 5, 2024, and July 19, 2024.

Joe La Rosa, CEO of La Rosa, commented, “This milestone marks a significant step in our mission to streamline our capital structure and enhance shareholder value. By fully redeeming and extinguishing these Warrants, we are reinforcing our commitment to building a solid foundation for the Company’s sustained growth and long-term success. We believe there is a significant disconnect between the market valuation and the true value of the Company. As we focus on eliminating debt and strengthening our balance sheet, we remain dedicated to achieving profitability in 2025 by acquiring additional real estate brokerage firms, growing our agent network, and expanding into new markets.”

In addition, Joe La Rosa, CEO of La Rosa Holdings Corp., will be featured in a podcast interview with Zack Morris on Wednesday, January 29th, 2025, at 4:00 PM EST. Click here to tune in.

The closings of the acquisitions mentioned in this press release are subject to, and contingent upon, the execution of definitive agreements and other related transaction documents by the parties, corporate approval and customary closing conditions. There can be no assurances that these transactions will be consummated.

‍

NEWS


La Rosa Holdings Corp. Reports 119% Year-Over-Year Increase in Revenue to $69.4 Million for Fiscal 2024; Surpassed Initial Revenue Guidance by Approximately $4.4 Million

4 hours ago

La Rosa Holdings Corp. Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

2 days ago

La Rosa Holdings Corp. Launches LR Agent Advance, Delivering Commission Advances for its Real Estate Agents

Apr 8, 2025

La Rosa Holdings Corp. to Expand into Europe with the Engagement of Real Estate Veteran Joaquín Nuevo Alarcón as Area Developer for Spain

Feb 25, 2025

La Rosa Holdings Corp. Announces $4.96 Million Private Placement to Fund Future Potential Strategic Acquisitions, Reduce Debt, and Strengthen Balance Sheet

Feb 6, 2025

La Rosa Holdings Corp. Appoints Commercial Real Estate Veteran JM Padron to Lead National Expansion of Commercial Real Estate Division

Jan 30, 2025

La Rosa Holdings Corp. Strengthens Balance Sheet by Redeeming and Extinguishing a Large Portion of Outstanding Warrants

Jan 28, 2025

La Rosa Holdings Corp. Reports Unaudited Preliminary Revenue of Approximately $65 Million for Fiscal Year 2024, Achieving 104% Year-Over-Year Growth

Jan 23, 2025

La Rosa Holdings Corp. Acquires Real Estate Brokerage Franchisee with Approx. $2.7 Million in Revenue for Trailing Twelve Months and Positive Net Income as of November 30, 2024

Jan 8, 2025

La Rosa Holdings to Offer Bitcoin and Cryptocurrency Payment Options to its Real Estate Agents

Dec 23, 2024

La Rosa Holdings Launches its First Office in North Carolina

Dec 11, 2024

La Rosa Holdings Reports 155% Year-Over-Year Increase in Revenue to $51.7 Million for the First 9 Months of 2024; Surpassing Initial Revenue Guidance by Approximately $6.7 Million

Nov 20, 2024

La Rosa Holdings Corp. Acquires 100% Ownership of La Rosa Realty Premier Franchisee with Approx. $2.09 Million in Revenue and Positive Net Income for 2023

Nov 13, 2024

La Rosa Holdings to Unveil Proprietary Technology Advancements at Growth Summit 2024

Nov 7, 2024

La Rosa Holdings to Present at the LD Micro Main Event XVII on October 29th

Oct 24, 2024

La Rosa Holdings Reports Preliminary 9-Month Revenue for 2024 of Approximately $45 Million, Reflecting 120% Year-Over-Year Growth

Oct 23, 2024

La Rosa Holdings Launches My Agent Account Version 3.0 with Enhanced Property Management Disbursement Features; Expected to Enhance La Rosa’s Agents’ Productivity and Efficiency by 50% by Year-End

Oct 9, 2024

La Rosa Holdings Announces Debt Restructuring; Conversion Rights Halted and Principal & Interest Payments Deferred Until February 2025

Sep 26, 2024

iAccess Alpha’s Buyside Best Ideas Virtual Fall Conference September 24-25, 2024

Sep 20, 2024

La Rosa Holdings to Participate in iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024

Sep 18, 2024

MANAGEMENT TEAM

Joe La Rosa

JOE LA ROSA

FOUNDER & CEO
  • Board of Directors, NAR
  • Muti Company Entrepreneur
  • Life and business Development Coach
  • Philanthropist
  • 18 years real estate experience
Kent Metzroth

KENT METZROTH

CHIEF FINANCIAL OFFICER
  • Over 20 years of domestic and international experience in multiple industries
  • Former SVP, Treasurer, Investor Relations & Business Finance of a multinational company
Alex Santos

ALEX SANTOS

CHIEF TECHNOLOGY OFFICER
  • BS Computer Science
  • 25+ Years Web Development & Technology Solutions with experience creating secure and scalable web applications.
Tiffany Polite

TIFFANY POLITE

DIRECTOR OF COACHING
  • 5+ years in Real Estate industry as Agent and coach
  • 10 years or management and coaching experience
Pedro Aguilar

PEDRO AGUILAR

DIRECTOR OF EDUCATION
  • 7+ years in the Real Estate industry as Agent and coach
  • 10+ years as Instructor for U.S. Marine Corps Recruiting to drive recruiting goals throughout nationwide Recruiting Stations
Lissette Ortolani

LISSETTE ORTOLANI

DIRECTOR OF RECRUITING
  • Recruiter, manager and trainer within the real estate and insurance fields with over 10 years of experience
Brian Kirkwood

BRIAN KIRKWOOD

DIRECTOR OF MARKETING
  • BS Business Administration
  • 7 Years with The Walt Disney Company
  • Development and implementation of brand and marketing identity for multiple companies

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF NINE THOUSAND SEVEN HUNDRED FIFTY USD BY SHORE THING MEDIA LLC FOR A ONE DAY LRHC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

USAU

***Sponsored by Sideways Frequency, LLC

READ THE INVESTOR PRESENTATION HERE

_________________________

‍

Hello Everyone,

This has been a great environment for Gold. Physical gold, gold stocks, gold ETF’s etc. have all been performing well. Gold giant Newmont Mining is up roughly 50% in 2025, among other big gold companies that are performing well.

We have a past winner back in the forefront for Wednesdays session. You will definitely remember this one.

We brought it to you back in November when it was sitting around 6.20.

Then we showed it to you again in mid January when it was a little over 7.50.

In early Feb again we said you should research this company while it was still under $8.

Since then we have seen this company top out at the 52 week high of 11.75!

Pretty good right?

USAU is sitting strong, hovering right around the 10 buck mark right now.

Why all the buzz about USAU? That really cannot be summed up in a sentence but there is no denying that this has been a “right place, right time scenario”.

Roth Capital Partners recently initiated coverage of the company with a Buy rating and a price target of $10, calling the company “undervalued” based on its CK Gold Project.

Paradigm Capital also had positive coverage, with a Speculative Buy rating and a target price of $16.50. Paradigm’s analysts highlighted that the CK Gold Project, now fully permitted and shovel-ready, is positioned to become Wyoming’s next major gold and copper mine.

We also saw HC Wainwright raise their price objective on U.S. Gold from $11.00 to $13.00 and gave the stock a “buy” rating in a research report In late November.

USAU is also sitting in the portfolio of significant Wall Street players like JP Morgan Chase & Co, Jane Street Group, Prospera Financial Services & Geode Capital Managment to name a few.

Commonwealth Equity Services LLC purchased a new stake in U.S. Gold Corp. in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 31,000 shares of the technology company’s stock, valued at approximately $190,000.

Gold has been constantly in the news cycle over the past few years now since inflation started running wild.

Many top analysts are saying that gold stocks are poised to perform well in 2025 due to a combination of global economic uncertainties, inflationary pressures, and a stable demand for safe-haven assets. Inflation concerns continue to exist, pushing investors toward gold as a store of value. Geopolitical tensions and economic volatility create an environment where gold remains an attractive hedge against risk. As demand for gold remains strong and production becomes more efficient, gold companies offer a compelling investment opportunity for those seeking exposure to the precious metal while benefiting from the potential upside of well-managed mining operations.

U.S. Gold Corp. (NASDAQ: USAU) is an emerging gold and copper exploration and development company positioned to benefit from the ongoing bull market in gold.

The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 601 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 77 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho.

With a focus on shovel-ready projects and a strategic location in a mining-friendly jurisdiction, U.S. Gold Corp aims to capitalize on rising gold prices. The company generates revenue primarily through the development of its mineral assets, particularly the CK Gold Project in Wyoming.

This project is one of the few permitted and shovel-ready gold and copper endeavors in North America, allowing for a streamlined path to production!

The company’s Keystone project in Nevada is very unique. It is a standalone district-scale project, located near Barrick’s flagship Cortez complex. It has very similar geology and stratigraphy to its neighbor, Cortez. It is USAU’s belief that a number of significant gold deposits are hosted at Keystone, and it is eagerly awaiting market conditions to improve so that we can explore Keystone with the level of interest that it deserves. It is a company maker in its own right.

U.S. Gold Corp plans to leverage its gold and copper reserves to maximize profit margins. With rising gold prices and stable energy costs, the company stands to benefit significantly as market conditions favor gold mining operations.

Company Highlights

  • USAU is one of the only permitted, shovel-ready gold/copper projects in North America that is yet to be developed. Producing companies are desperate to replace dwindling ounces from their production assets. Other companies are looking to increase their production profiles to garner a re-rating from the mining analysts. US Gold is in a unique situation due to this and the M&A interest it will generate as the mining sector gains momentum.
  • Jurisdiction: The company’s asset is in the safest mining jurisdiction on the planet-State of Wyoming land. Wyoming is a resource/mining friendly area, with no federal nexus. This was hugely important to the permitting process of the CK Gold project and its ongoing development.
  • US senior exchange listing: USAU trading on the NASDAQ affords the company the ability to access retail investors throughout the US as well as institutional investors globally. With a very tight share structure, the company is very well positioned to make the most out of this burgeoning bull market.
  • Copper: USAU’s copper component offers diversification of the asset for those who aren’t bullish on the gold-cycle.
  • Other value metrics around the CK project that have not been valued into the company yet. New generation is going to be key as USAU unlocks these value markers.

Properties

CK Gold Project – Near-Term Gold – Copper Producer

The CK Gold Project deposit is a development stage, large-tonnage, gold-copper deposit with high-grade mineralization exposed at the surface surrounded by a large, low-grade zone with potential for expanding resources.

The CK Gold Project was reportedly discovered in 1881, high-graded and saw limited mining. The first exploration work reported is drilling by ASARCO in 1938. Several additional rounds of drilling have been conducted since that time. In 1972 Henrietta Mines Ltd. acquired the property and completed a comprehensive program of exploration and development. In addition to drilling, an I.P. survey, geologic mapping, geochemical sampling, and metallurgical testing were conducted (Nevin, 1973). Drilling campaigns were conducted by Saratoga since 2006 and Strathmore since 2012, with a hiatus in drill exploration until the acquisition of the project by U.S. Gold Corp. from Energy Fuels in 2014. U.S. Gold Corp. conducted drilling in 2017, 2018, 2020 and is currently concluding its 2021 drilling program, focused on data collection to support post PFS and feasibility studies in 2022.

The CK Gold Project property is located in the Silver Crown mining district of southeast Wyoming, approximately 20 miles west of the city of Cheyenne, on the southeastern margin of the Laramie Range. The property comprises about 1,120 acres (2 square miles) and is 100% owned by U.S. Gold Corp. (NASDAQ: USAU).

In December 2021, the company released the project’s SK-1300 Technical Report Preliminary Feasibility Study, PFS (by Gustavson Associates LLC). The project offers the company near-term, open-pit production potential as well as compelling value.

Production potencial

Highlights:

  • 1.44 million AuEq Proven & Probable oz Reserve
  • Advantageous infrastructure, located near major highways and railroads, facilitates easy transportation of materials to smelters. This infrastructure advantage enhances the project’s economic viability.
  • 100K+ oz AuEq Annual Production Forecast – plus significant upside
  • Mineral Resource Expansion – open at depth and laterally
  • All In Sustaining Cost (AISC) of $800 AuEq/ oz over LOM
  • Low Strip Ratio – surface mineral outcrop with immediate revenue potential
  • Study Underway Analyzing Aggregate Potential
  • Final Stages of Permitting with WY government – no federal permits needed.
CK Gold Project Pre-Feasibility Study Summary*
Data
*Source:SK-1300 TechnicalReport Pre-FeasibilityStudy on the CK Gold Project report date December 1, 2021 using $1625 Au, $3.25 Cu and $18 Ag. Please see “CautionaryNote ConcerningMineral Resources”in this presentation

The Copper Situation

Prefeasibility Study Highlights of Ck Gold also include a staggering copper amount:

  • M+I includes: Gold – 1.110 million ounces and Copper – 280 million lbs!!!

Why is this a big deal?

Because copper will be a big part of the clean revolution.

Besides clean energy technologies, several industries including construction, infrastructure, and defense use copper for its unique properties. The metal is critical in many fast-growing clean industries from the electric grid and electric vehicles to renewable technologies.

Copper is essential in electrical wiring and transportation and is playing an increasingly large role in alternative energy, as it is a crucial component in wind turbines, solar panels, and electric vehicles, which require four times as much copper as conventional gas vehicles!

Some of the world’s largest mining companies and metal traders are warning that by 2025, a massive shortfall will emerge for copper, which is now the world’s most critical metal due to its essential role in the green economy.

The deficit will be so large that The Financial Post stated that it could itself hold back global growth, stoke inflation by raising manufacturing costs and throw global climate goals off course.

The copper supply issue is scary. There may not be enough copper to go around for the millions of electric vehicles (EVs) expected to hit the roads, or to fuel wind turbines and solar power.

In fact, wind and solar energy use more copper than conventional forms of energy, such as coal, natural gas, and nuclear power plants. Conventional power plants require about one ton of copper to produced one megawatt of electricity, whereas wind and solar can require between three to five tons per megawatt!

To make matters worse, these numbers only reflect the amount of copper needed to build wind turbines or solar panels, and do not factor in the additional copper needed to transport the electricity generated from wind and solar facilities to the population centers that consume the electricity.

The Next Milestones for the CK Gold Project:

  1. Publishing an updated Prefeasibility Study (“PFS”), now slated for early 2025;
  2. Continuing onto a final Feasibility Study (“FS”), which has already been advanced but awaits completion of the updated PFS to verify optimizations announced in September, including a final decision on the preferable flotation technology; and
  3. Development financing opportunities with several interested parties who have been following the Company’s progress with interest.

All these activities are planned to occur during 2025 and development, subject to suitable financing, could commence as soon as year-end 2025.

U.S. Gold Corp. Announces Inaugural Digbee Assessment Results

As U.S Gold Approaches Financing Activities for the CK Gold Project, the Assessment Demonstrates that the Company is on the Right Track to Satisfy Lenders

CHEYENNE, Wyo., Feb. 26, 2025 /PRNewswire/ — U.S. Gold Corp. (“U.S. Gold,” the “Company,” “we,” “our” or “us”) (NASDAQ: USAU), is pleased to announce the results of an independent assessment conducted by Digbee Limited (“Digbee”). Digbee’s platform provides companies a right-sized, future-looking set of globally aligned sustainability frameworks. Digbee evaluates a comprehensive range of factors—considering both a project’s context and the effectiveness of management actions—to assign a rating from AAA to D. The overall inaugural BBB score achieved by U.S. Gold, largely for its CK Gold Project, reflects the average across all assessment criteria. We believe this rating endorses our progress and confirms that we are on track to meet and exceed the risk review criteria set by financing entities.

Operating and conducting business responsibly, by respecting local communities, protecting the environment, and maintaining strong business practices is not just about gaining acceptance and following best practices; it’s also good business sense. Companies that embed responsibility into their core operations build stronger stakeholder relationships, mitigate risks, and create long-term value. This acceptance is not only necessary for securing permits but also for obtaining the social license to operate. To date, U.S. Gold has received permits to develop its CK Gold Project in southeast Wyoming, and as we progress toward securing project financing, development lenders require assurances that all potential project risks have been addressed. These risks can span a wide spectrum, including governance (ensuring the company adheres to established business practices), environmental (complying with laws, regulations, and practices to prevent and mitigate damage to natural surroundings), and social factors (engaging local communities and securing their acceptance of project development). Development lenders, through experience, have gathered criteria to evaluate whether risks have been addressed, and their investment is secure. The Digbee platform not only helps guide companies in their activities, but it also provides investors with some comfort through an independent review that confirms risks—measured against a wide range of criteria and international best practice—have been addressed.

George Bee, President and CEO of U.S. Gold, said, “Over the last four years, we have endeavored to do things ‘the right way,’ reaching out to the local community and authorities and taking care that our disturbances resulting from exploration activities are cleared up as we go along. That same responsible attitude and the desire to be a ‘good neighbor’ as we get into development and operation is top of mind. We are pleased to share the results of this independent assessment of our activities. The assessment shows where we can still do better, but overall the BBB rating at this early stage is a great endorsement that we are on the right track as we move toward development.”

Mr. Jamie Strauss, the founder and CEO of Digbee, commented, “U.S. Gold’s completion of the Digbee assessment underscores its commitment to responsible development and transparency. By proactively evaluating risks and opportunities, the Company is positioning itself to build long-term value while meeting the evolving expectations of investors and stakeholders. This is a crucial step in demonstrating leadership and resilience in today’s mining landscape.”

The results of the Digbee assessment are available and summarized on the Company’s website and can be accessed by following the link here.

Keystone Project

Discovering the next major gold opportunity on the Cortez Trend in Nevada!

  • An established gold mining jurisdiction
  • Produced ~4.47 M oz of gold produced in 2021 – approx. 78% of U.S. gold production *USFunds.com
  • 6th largest gold producing “country” in the world, if Nevada were a country
  • Historically, Nevada has produced > 225M oz of gold, hosting numerous world-class deposits
  • “Elephant country”: >20M oz gold deposits
  • Pro-mining environment, geopolitical stability, major infrastructure Keystone Project Location Keystone exhibits many similarities to Barrick’s deposits to the north; similar host rock, stratigraphy, structure and Eocene intrusions

Priority Target Areas:

  • Consolidated an entire district on the Cortez Trend, NV – 20 square miles, 100% controlled by U.S. Gold Corp.
  • Never previously consolidated nor systematically explored by model -driven, modern -day exploration techniques
  • The extent and intensity of the alteration and the thickness of permissive rock packages encountered, highlight the potential of this district-scale mineral system
  • Systematic exploration has primed Keystone for discovery
  • Recent hyperspectral survey undergoing ground investigation for potential additional targets

Cortez Complex Comparison to Keystone:

Data3

‍

NEWS


THE Mining Investment Event – Quebec City, June 3-5, 2025 Announces Glencore Canada Exclusive Diamond Sponsor New Sponsors and Participating Issuers

Mar 31, 2025

U.S. Gold Corp. to Participate at the 37th Annual ROTH Conference for Growth Companies in Dana Point, California

Mar 14, 2025

U.S. Gold Corp. Announces Inaugural Digbee Assessment Results

Feb 26, 2025

U.S. Gold Corp. Announces Updated Prefeasibility Study Results

Feb 11, 2025

U.S. Gold Corp. to Participate at the 2025 Future Minerals Forum in Riyadh, Saudi Arabia

Jan 9, 2025

U.S. Gold Corp. Provides Commentary on $10.2 Million Non-Brokered Registered Direct Offering and CK Gold Project Update

Dec 11, 2024

U.S. Gold Corp. Closes $10.2 Million Non-Brokered Registered Direct Offering

Dec 6, 2024

U.S. GOLD CORP. ANNOUNCES $10.2 MILLION REGISTERED DIRECT OFFERING

Nov 27, 2024

U.S. Gold Corp. to Participate in New Orleans Investment Conference and CEM Florida Capital Event November 20-24

Nov 20, 2024

U.S. Gold Corp. Receives Air Quality Permit, Finalizing the Mine Operating Permit for the CK Gold Project

Nov 18, 2024

U.S. Gold Corp. Chairman to Appear on Live Gold Panel “Mined in the USA”

Oct 30, 2024

Winning Media Announces Exclusive Interview With US Gold Corp Chairman and Co-Founder, Luke Norman

Oct 8, 2024

U.S. Gold Corp’s Fall Conference Takeaway Spotlights Developers with Permitted, Derisked Projects in Mining-Friendly Jurisdictions

Sep 25, 2024

U.S. Gold Corp. to Participate at the Gold Forum Americas 2024 Conference in Colorado Springs, Colorado

Sep 11, 2024

U.S. Gold Corp. Provides Update on Engineering Optimization Studies for CK Gold Project

Sep 4, 2024

U.S. Gold Corp. to Participate at the 2024 Precious Metals Summit in Beaver Creek, Colorado

Aug 29, 2024

U.S. Gold Corp. to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York

Aug 21, 2024

U.S. Gold Corp. Proud Sponsor of the 128th Annual Cheyenne Frontier Days – July 19-28, 2024

Jul 10, 2024

US Gold Corp CEO highlights CK Gold Project’s strategic and environmental advantages

Jul 8, 2024

U.S. Gold Corp. Completes Second of Three Mine Operating Permit Conditions for the CK Gold Project in Wyoming

Jun 20, 2024

https://fintech.tv/
https://fintech.tv/

‍

MANAGEMENT

George Bee

PRESIDENT AND CEO

Mr. Bee is a senior mining industry executive, with deep mine development and operational experience.  He has an extensive career advancing world-class gold mining projects in eight countries on three continents for both major and junior mining companies.  Most recently in 2018 Mr. Bee concluded a third term with Barrick Gold as Senior VP Frontera District in Chile and Argentina to advance Pascua Lama feasibility as an underground mine. This capped a 16-year history with Barrick Gold with positions that included Mine Manager at Goldstrike during early development and operations, Operations Manager at Pierina Mine taking Pierina from construction to operations, and General Manager of Veladero developing the project from advanced exploration through permitting, feasibility and into production.

With his Barrick experience and having had eight years in South Africa working underground gold with Anglo American and open pit copper with Rio Tinto at Palabora Mine, Mr. Bee was well placed to advance projects internationally and domestically as a senior executive. This led to his appointment to various board and leadership positions at various companies. As COO of Aurelian Resources in 2007, he was in charge of project development for Fruta del Norte in Ecuador until Aurelian was acquired by Kinross Gold in 2008. Post-acquisition, moving on from Kinross, where he had also previously worked from 1996 to 1998 advancing projects in El Salvador and Nevada, he joined Andina Minerals as CEO in 2009. Andina and its 6 million-ounce Volcan Gold Project in Chile was acquired by Hochschild in 2013. By this time Mr. Bee had been appointed to the boards of Peregrine Metals and later Stillwater Mining and Jaguar Mining. In 2014, he also assumed the role of Chief Executive Officer of Jaguar Mining, operating mines in Brazil, as the company emerged from a financial restructuring process.

Mr. Bee is a graduate of the Camborne School of Mines in Cornwall, United Kingdom and is a member of the Institute of Corporate Directors with an ICD.D designation.

Eric Alexander

CHIEF FINANCIAL OFFICER AND CORPORATE SECRETARY

Mr. Eric Alexander has over 30 years of corporate, operational and business experience, and over 15 years of mining industry experience. Previously he served as Corporate Controller of Helix Technologies, Inc., a publicly traded software and technology company from April 2019 to September 2020. Prior to that, he served as the Vice President Finance and Controller of Pershing Gold Corporation, a mining company (formerly NASDAQ: PGLC), from September 2012 until April 2019. Prior to that, Mr. Alexander was the Corporate Controller for Sunshine Silver Mines Corporation, a privately held mining company with exploration and pre-development properties in Idaho and Mexico, from March 2011 to August 2012. He was a consultant to Hein & Associates LLP from August 2012 to September 2012 and a Manager with Hein & Associates LLP from July 2010 to March 2011. He served from July 2007 to May 2010 as the Corporate Controller for Golden Minerals Company (and its predecessor, Apex Silver Mines Limited), a publicly traded mining company with operations and exploration activities in South America and Mexico. In addition to his direct experience in the mining industry, he has also held the position of Senior Manager with the public accounting firm KPMG LLP, focusing on mining and energy clients. Mr. Alexander has a B.S. in Business Administration (concentrations in Accounting and Finance) from the State University of New York at Buffalo and is also a licensed CPA.

Kevin Francis

VICE PRESIDENT – EXPLORATION & TECHNICAL SERVICES

Mr. Francis has held many senior roles within the mining industry, including VP of Project Development for Aurcana Corporation, VP of Technical Services for Oracle Mining Corporation, VP of Resources for NovaGold Resources and Principal Geologist for AMEC Mining and Metals. Most recently, he consulted to U.S. Gold Corp. as Principal of Mineral Resource Management LLC, a consultancy providing technical leadership to the mining industry, as well as the CK Gold Project through his association with Gustavson Associates (a member of WSP) since September 2020. Mr. Francis is a member of the Board of Directors of Texas Mineral Resources Corporation. Mr. Francis is a “Qualified Person” as defined by SEC S-K 1300 and Canadian NI 43-101 reporting standards and holds both an M.S. degree and a B.A. in geology from the University of Colorado.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND SEVEN HUNDRED FIFTY USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY USAU AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

NLSP

***Sponsored by LFG Equities Corp

‍

READ THE INVESTOR PRESENTATION HERE

________________________

‍Hello Everyone,

We’re coming off another action-packed week in the markets — full of volatility, heavy swings, and uncertainty. But even in the chaos, some companies are showing resilience and moving steadily forward. One of those names you should be watching closely is NLS Pharmaceutics (NASDAQ: NLSP).

Why NLSP Stands Out

NLSP is a clinical-stage pharmaceutical company developing innovative therapies for patients with rare and complex central nervous system (CNS) disorders — particularly in areas where existing treatments are insufficient or non-existent.

One of the fastest-growing sectors in global healthcare is ADHD, a market projected to reach $70+ billion by 2032. NLSP’s lead candidate, Mazindol ER, directly addresses this space — and more.

Mazindol ER: A Phase 3-Ready Asset with Broad Potential

Mazindol ER is an extended-release formulation of a well-studied compound with a proven safety profile. It’s Phase 3-ready for both:

  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Narcolepsy and Excessive Daytime Sleepiness (EDS)

With Orphan Drug Designation in both the U.S. and Europe, and a strong Phase 2 data package in hand, Mazindol ER is positioned to move swiftly through the regulatory pipeline. The upcoming AMAZE Phase 3 trial will focus on adult patients with narcolepsy, a $4.5 billion market projected by 2027.

Strategic Expansion: Tackling the Opioid Crisis

In a significant step beyond CNS and sleep disorders, NLS also holds a U.S. patent for the use of Mazindol ER in treating opioid use disorder, including heroin and fentanyl addiction. A preclinical study targeting fentanyl addiction is underway and is expected to yield promising results.

This positions NLSP within the $5 billion opioid addiction treatment market, a high-priority area for the U.S. government and public health institutions. With fentanyl-related overdoses now the leading cause of drug-related deaths in the U.S., the need for non-opioid alternatives has never been greater. Mazindol ER’s unique pharmacological profile — modulating dopaminergic and noradrenergic pathways without being addictive — makes it a compelling candidate in this space.

‍

Corporate HIGHLIGHTS

  • Clean balance sheet: No debt, $3.2M raised, 12-month cash runway
  • Nasdaq compliance regained
  • Merger in progress: Binding term sheet signed with Kadimastem, a clinical-stage biotech with complementary assets and commercial expertise
  • Pipeline strength: Over 100 patents in 140+ countries covering CNS, ADHD, cancer fatigue, Parkinson’s, and more
  • Named Patient Program launched in Europe for idiopathic hypersomnia
  • Multiple partnerships: Including Université de Lausanne, University of Berne, Swiss Narcolepsy Network, and patient advocacy organizations such as Narcolepsy Network and Hypersomnia Foundation

Product Pipeline Highlights

  • Quilience® – Targeting EDS and cataplexy in narcolepsy
  • Nolazol® – In development for ADHD and related neurodevelopmental disorders
  • IsletRx (via merger with Kadimastem) – A regenerative cell therapy targeting insulin-dependent diabetes

Why This Matters

NLS isn’t just riding the momentum of emerging markets in ADHD and sleep disorders — they’re seeking to build long-term value through intelligent pipeline development, strategic IP, and a focus on real-world, unmet clinical needs. And now, with its entrance into the fight against opioid addiction, NLSP adds a compelling new dimension to its mission.

In a market that punishes hype and rewards substance, NLSP is on the path to quietly execute.

‍

NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH, March 10, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholder.

Dear Shareholders,

We are thrilled to share the significant progress and strategic milestones NLS Pharmaceutics has achieved, positioning our company for a transformative future in the biotechnology sector.

Strategic Merger with Kadimastem

In November 2024, we announced a definitive merger agreement with Kadimastem Ltd. (TASE: KDST) (“Kadimastem”), a clinical-stage cell therapy company specializing in “off-the-shelf” allogeneic cell products for neurodegenerative diseases and diabetes. This merger aims to create a Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies. Both companies’ boards of directors have unanimously approved the transaction, with Kadimastem’s shareholders recently voting in favor and NLS major shareholders holding approximately 40% of NLSs’ common shares having signed support letters for the NLS shareholders’ meeting to be convened soon. We currently anticipate closing the merger in the second quarter of 2025, pending effectiveness of NLSs’ pending registration statement filed with the Securities and Exchange Commission (“SEC”), Nasdaq approval, NLSs’ shareholders’ approval and customary closing conditions.

Regulatory Filings and Approvals

We filed a Registration Statement on Form F-4 and subsequent amendment with the SEC, detailing the proposed merger with Kadimastem. This filing is a necessary step toward finalizing the merger and creating a combined entity focused on innovative therapies. In addition, we have submitted an application to list the merged company on Nasdaq under the name of “NucelX Ltd.”, with the future ticker of NCEL.

Advancements in Diabetes Treatment

In collaboration with iTolerance Inc., Kadimastem has successfully completed a pre-Investigational New Drug (“pre-IND”) meeting with the U.S. Food and Drug Administration(“FDA”) for iTOL-102, a potential breakthrough therapy for Type 1 Diabetes. This innovative approach combines Kadimastem’s IsletRx cells with iTolerance’s immunomodulator, aiming to cure Type 1 Diabetes without the need for lifelong immune suppression.

The diabetes treatment landscape has experienced significant growth, underscored by notable mergers and acquisitions. For instance, Novo Nordisk’s acquisition of Inversago Pharma for up to $1.075 billion highlights the strategic emphasis on developing novel therapies for obesity, diabetes, and related metabolic disorders. Similarly, Roche’s $2.7 billion acquisition of Carmot Therapeutics reflects their concerted effort to expand into the diabetes and obesity markets. Additionally, Sana Biotechnology has made significant advancements in the diabetes space, with early clinical data suggesting their hypo immune platform could enable insulin production without immunosuppression, positioning them as a potential leader in developing transformative treatments for type 1 diabetes. We believe that these developments underscore the sector’s robust growth and the immense potential it holds for innovative treatments.

Furthermore, we are expanding our diabetes treatment strategies beyond GLP-1 therapies. By integrating complementary approaches, we aim to address the multifaceted challenges of diabetes management, including neuroinflammation and metabolic resilience.

Advancements in Neurodegenerative Disease Treatment

Post-merger, we plan to prepare and initiate a Phase IIa multi-site clinical trial of AstroRx®, Kadimastem’s product candidate for Amyotrophic Lateral Sclerosis (ALS). This trial is slated to commence following the merger’s completion, marking significant progress in our neurodegenerative disease treatment pipeline.

Experienced International Leadership Team

We believe that Kadimastem contributes to the merger with its experienced international leadership team and board of directors, and with the teams prior experience developing medicine from the laboratory to the market. For example, Rebif®, a blockbuster drug invented by Professor Michel Revel, Chief Scientist at Kadimastem, in his capacity as a scientific investigator at the world-renowned Weizmann Institute of Science, was acquired by Merck Serono. In addition, Ronen Twito, Kadimastem’s Executive Chairman and Chief Executive Officer, brings extensive experience working in the U.S. capital market and M&A international market.

Advancements in DOXA R&D Programs

Our promising Dual Orexin Receptor Agonist (“DOXA”) platform has made significant strides. The development of AEX-41 and AEX-2 compounds showcases our dedication to addressing unmet needs in sleep-wake disorders. Preliminary studies have yielded promising results, reinforcing our confidence in these compounds’ potential to transform patient care.

Additional Pipeline Expansion and Research Initiatives

Our commitment to addressing critical health challenges remains steadfast:

  • Fentanyl Dependence Treatment: We have launched a preclinical program evaluating Mazindol ER as a treatment for fentanyl dependence, aiming to offer a non-opioid alternative in combating the opioid crisis.
  • Advancing Scientific Research: Our recent submissions to and upcoming poster presentation at the American Society of Clinical Psychopharmacology’s 2025 Annual Meeting highlight our commitment to innovative therapeutic strategies and groundbreaking research.

Financial Resilience and Growth

We have fortified our financial foundation through strategic initiatives:

Nasdaq & Strong Financial Position

  • We carry zero long-term debt, a rarity among biopharmaceutical companies. This strong financial position provides us with flexibility to execute our strategic goals without financial constraints.
  • We raised approximately $4.2 million pursuant to private placements in October and December 2024, at a premium to market price. We currently believe that the amounts raised in these private placements has extended our operational runway to approximately 18 months.
  • This financial stability empowers us to accelerate clinical development, pursue strategic partnerships, and advance our innovative pipeline with confidence.

Looking Ahead

The momentum generated by these developments underscores our commitment to delivering life-changing therapies. We aim to capitalize on emerging opportunities within the dynamic biotechnology landscape, driving NLS Pharmaceutics toward a future of unparalleled success.

As we embark on this exciting new chapter, we remain laser-focused on:

  • Building an international, strong, well-balanced pipeline and top-notch biotechnology company
  • Delivering life-changing therapies for patients worldwide
  • Expanding our pipeline through innovation & strategic collaborations
  • Maximizing shareholder value by maintaining a strong financial position

We extend our deepest gratitude to our shareholders, partners, and supporters for your trust and commitment. Together, we are building a future of unparalleled success for NLS Pharmaceutics.

Sincerely,

Alex ZwyerChief Executive Officer

NLS Pharmaceutics (NASDAQ: NLSP)

PIPELINE

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

  • Centers for Disease Control and Prevention (the “CDC”) reported 105,007 drug overdose deaths – with 90% involving synthetic opioids like fentanyl
  • Mazindol ER potentially offers a non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction.
  • Mazindol ER is patent protected beyond September 2038

ZURICH, Jan. 28, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is proud to announce the launch of a preclinical program evaluating Mazindol ER (Extended-Release) as a novel treatment for fentanyl dependence. Fentanyl dependence is a major global health crisis and was recently declared a national public health emergency by the new Trump administration. In 2023, the CDC reported 105,007 drug overdose deaths with 90% involving synthetic opioids like fentanyl.

“The opioid epidemic, and specifically the rise of fentanyl dependence, presents an urgent medical need for innovative, non-opioid treatment approaches,” said Alex Zwyer, Chief Executive Officer of NLS. “We are committed to exploring the unique pharmacological profile of Mazindol, which targets multiple neurotransmitter systems implicated in opioid addiction. This preclinical program represents an important step in developing a potentially transformative therapy.”

Highlights of the Preclinical Program Mazindol, a tetracyclic compound with a distinct pharmacological profile, has shown potential in mitigating opioid dependence by acting on multiple neurotransmitter pathways, including:

  • 5-HT1A receptor modulation: Regulates mood, anxiety, and reward pathways, addressing psychological aspects of opioid withdrawal.
  • Mu-opioid receptor (“MOP”) interaction: Provides partial modulation of opioid effects, potentially reducing cravings and withdrawal symptoms without reinforcing addiction.
  • Orexin-2 receptor (“OX2R”) partial agonist: Aids in restoring sleep-wake cycles and enhancing cognitive stability, which are significantly disrupted during opioid withdrawal.

Scientific RationaleFentanyl, a synthetic opioid that is up to 50 times more potent than heroin, has driven a global health crisis due to its high abuse potential and severe withdrawal symptoms. Traditional treatments, such as methadone and buprenorphine, often come with limitations, including risk of dependence and regulatory hurdles.

Mazindol ER offers a potential non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction while supporting recovery through its multimodal action on neurotransmitter systems. The sustained-release formulation provides a long-acting therapeutic effect, improving patient compliance and minimizing withdrawal-related disruptions.

Mechanism of Action of Mazindol ERMazindol’s unique pharmacodynamic properties position it as a promising candidate for opioid dependence treatment. Its mechanisms include:

  • Inhibition of dopamine and norepinephrine transporters, restoring neurochemical balance and reducing cravings.
  • 5-HT1A receptor modulation, potentially alleviating anxiety and depressive symptoms associated with withdrawal.
  • MOP agonist activity, which may help mitigate opioid withdrawal symptoms while preventing full opioid reinforcement.
  • Partial OX2R agonist activity, aiding in circadian rhythm regulation and reducing the impact of opioid-induced sleep disturbances.

Preclinical Study Objectives and Next Steps

The preclinical study, designated Study KO-943, will focus on:

  1. Evaluating the safety and efficacy of Mazindol ER in fentanyl dependence models.
  2. Assessing pharmacokinetics and pharmacodynamics in opioid-exposed subjects.
  3. Exploring the impact of Mazindol ER on craving reduction, withdrawal mitigation, and cognitive performance.

The study is expected to be completed within 12-18 months. Upon successful results, NLS will potentially seek regulatory pathways to advance to clinical development.

“We believe that Mazindol ER could offer a paradigm shift in opioid addiction treatment,” added Dr. Konofal, M.D./PhD, Chief Scientific Officer of NLSP. “Our stepwise development plan prioritizes early-stage investment to generate critical data that will pave the way for larger-scale studies and potential commercialization opportunities.”

Existing Patent Portfolio

NLS Pharmaceutics has secured several patents supporting the development of Mazindol ER:

  • United States Patent No. 11,207,271: Covers oral formulations containing immediate-release and sustained-release layers of mazindol and their use in treating attention deficit disorders (“ADHD”) as well as sleep disorders.
  • United States Patent No. 11,596,622: Granted for the use of Mazindol ER in the treatment of heroin dependence, providing a new therapeutic strategy for opioid use disorder.

These patents strengthen the Company’s intellectual property position and support the ongoing development of Mazindol ER for various indications.

Future Outlook

NLS aims to utilize initial findings to expanded research and potential commercialization of Mazindol ER in the treatment of fentanyl dependence. Other pipeline candidates include:

  • NLS-4 (Lauflumide): A wake-promoting agent with applications in military and emergency response.
  • NLS-11 (Benedin): A circadian rhythm modulator with potential applications for space missions and the ultra-rare Kleine-Levin Syndrome (KLS).
  • NLS-3 (Levophacetoperane SR): A novel treatment for ADHD and Autism Spectrum Disorders, with potential pro-drug development.

‍

Lead Asset: Mazindol ER

Mazindol ER is a patented and proprietary formulation of the active compound mazindol, and are designed for once-daily dosing. Mazindol has a well-established safety record from its long history of clinical use in the United States and in Europe when the drug was approved in an immediate release formulation for the management of obesity. Mazindol was marketed for nearly 30 years under the trade name Sanorex® before being voluntarily withdrawn from the market, and the drug is no longer available nor marketed in these regions. During its time on the market, mazindol was also widely used off-label and prescribed under compassionate use for the treatment of narcolepsy for several decades. Use in these compassionate use programs has yielded evidence of positive efficacy in patents suffering from the symptoms of narcolepsy including patients that were refractory to approved treatments for the disorder. Additionally, these same programs, a retrospective analysis of investigator sponsored studies, and NLS’s own trial evaluating Mazindol ER in patients with ADHD provide evidence of the drug’s favorable safety profile at doses that yielded efficacy signals.

We believe that our lead product candidate,  Mazindol ER, offers a differentiated profile with clincally meaningful advantages over current treatment options for narcolepsy for the following reasons:

Mechanism of action

If approved, Mazindol ER would be the only partial orexin 2 receptor agonist as well as the only triple monoamine reuptake inhibitor approved by the FDA for the treatment of narcolepsy. Narcolepsy is caused by a profound loss of orexin producing neurons. A partial orexin 2 receptor agonist may help to replace missing endogenous orexin peptide, addressing the underlying cause of the disease. In addition, the drug’s action as a triple monoamine reuptake inhibitor can further reduce disease specific symptoms, offering patients a treatment option that may address the two primary symptoms of narcolepsy – excessive daytime sleepiness (EDS) and cataplexy attacks – in a convenient once-daily oral tablet.

Low potential for abuse, misuse, and diversion.

Mazindol is currently classified by the DEA as a Schedule IV controlled substance . The DEA defines Schedule IV controlled substances as those “with a low potential for abuse and a low risk of dependence”. Unlike Xyrem® (sodium oxybate), the top-selling treatment for narcolepsy in the United States deemed to have a high potential for abuse/misuse (Schedule III), mazindol was never required by the FDA to have a risk evaluation and mitigation strategy (REMS) program in place to manage known or potential serious risks associated with its use.

Quilience® has potential to be administered as a monotherapy.

Narcolepsy is a difficult disorder to manage and even with available treatments, the majority of narcolepsy patients often require multiple medications to treat their symptoms. According to the current treatment guidelines (initially published in 2007) of the American Academy of Sleep Medicine, or AASM, medications for narcolepsy, at best, provide only moderate improvement in narcolepsy symptoms, and their respective side effects may limit their use. The AASM specifically highlights that future investigations should be directed toward more effective and better tolerated therapies for treatment. The Voice of the Patient report from the FDA’s patient-focused drug development initiative, published in 2014, concluded that, based on the overall benefit-risk assessment of current medications, there is a continued need for additional effective and tolerable treatment options for patients with narcolepsy. A retrospective analysis (Nittur et.al, Sleep Med. 2013 Jan;14(1):30-6) showed that mazindol has a long-term, favorable benefit/risk ratio in 60% of drug-resistant patients with hypersomnia, including a clear benefit on the two primary symptoms of narcolepsy–EDS and cataplexy.

Mazindol ER is being developed as a once-daily oral tablet administered in the morning upon wakening.

Patients have identified a need for treatment options that are easier to take, dosed less frequently, do not disrupt nighttime sleeping, and provide full day coverage of symptoms. We believe that once-daily dosing with Mazindol ER may address this need and may help improve patient compliance and adherence with treatment. Mazindol ER utilizes our patented and proprietary extended-release (ER) formulation and is being designed to optimize its pharmacokinetic and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral dose that effectively provides consistent and long-acting symptom control to uniquely meet the needs of patients.

Relationship Between Narcolepsy and ADHD

Narcolepsy and psychiatric disorders have a significant but under-recognized relationship in which the two may coexist. However, narcolepsy is frequently misdiagnosed initially as a psychiatric condition, contributing to protracted times for accurate diagnosis and treatment. Narcolepsy is a disabling neurological condition that carries a high risk for the development of social and occupational dysfunction. Deterioration in function associated with narcolepsy may lead to the secondary development of psychiatric symptoms and inversely, the development of psychiatric symptoms can lead to a deterioration in function and quality of life. The overlap in treatments may further enhance the difficulty to distinguish between diagnoses.

ADHD is the most common neurobehavioral disorder characterized by symptoms of inattention, impulsivity and hyperactivity with an estimated prevalence rate of approximately 4-12% worldwide, as reported by the paper, “Understanding Attention Deficit/Hyperactivity Disorder From Childhood to Adulthood,” by Drs. Timothy E. Wilens and Thomas J. Spencer.

On the surface, ADHD may appear to be the opposite of narcolepsy; however, there may actually be significant clinical similarities between the two disorders. Cumulative data on sleep problems in children and adolescents with ADHD have shown that children with ADHD have had a higher rate of restless sleep, impaired sleep, and daytime sleepiness than children without ADHD. However, it is unclear whether EDS in ADHD is due to nocturnal sleep disturbances or primary vigilance disorders because shorter sleep onset latency is assessed in ADHD patients by the Multiple Sleep Latency Test, rather than in the control group irrespective of the presence/absence of sleep disturbances.

Alternatively, problems with sleep may represent an intrinsic component of ADHD. The presence of ADHD symptoms in children and adolescents with narcolepsy has been found to be about two-fold higher than in the general control population. Adults with narcolepsy have been found to have a much greater likelihood of having a diagnosis of ADHD in childhood compared to the general control population. Hyperactivity seen in ADHD may, in fact, be a compensatory response for individuals who are under-aroused or sleepy, and ADHD symptoms contribute to poor quality of life and increased frequency of depressive symptoms, similar to narcolepsy. To the best of our knowledge, almost all of the treatments used in ADHD have mechanistic overlap with treatments used in narcolepsy for EDS, and researchers suggest that the symptoms of EDS, fatigue, and sleep fragmentation may be the cause for ADHD symptoms, which is consistent with similar findings in other hypersomnia disorders.

AstroRx, the medical product for ALS treatment that is being researched by Kadimastem, the company NLSP has signed a binding merger agreement with, was granted Orphan drug status by the FDA. This status grants the company that manufactures the drug marketing exclusivity for 7 years from the date of receipt of marketing approval of the drug. The recognition of orphan drug status also enables accelerated examination and response paths from the FDA and other regulatory authorities.
‍

Additionally, Kadimastem is focused on the generation and manufacturing of pancreatic insulin secreting islets (IsletRx) from embryonic stem cells for the treatment of insulin dependent diabetes such as Type 1 Diabetes. This program is in pre-clinical phase and they are moving fast down the regulatory path to start human trials. The number of patients with diabetes was estimated to be over 366 million worldwide in 2011 and is projected to be more than 552 million in 2030.  The American Diabetes Association (ADA) estimated the total annual costs of diabetes to be US$223.5 billion (in the US alone). The global cost is estimated to be US$465 billion annually and will grow to about US$510 billion by 2030.

MANAGEMENT TEAM

AlexZwyer, MBA

Chief Executive Officer & Co-Founder

Alex Zwyer

A co-founder of the company with extensive operational, C-level pharmaceutical experience as well as a serial entrepreneur and strong leader with a proven track-record.

Alex Zwyer has served as our Chief Executive Officer and as a Director since our incorporation in August 2015. Mr. Zwyer has over 25 years of international business experience of which more than 10 years as a C-level executive in the pharma/biotech field. In 2007, prior to, and until founding NLS in 2015, Mr. Zwyer founded a startup in the high-end luxury food sector, and served as its chief executive officer until 2015 when he successfully sold the company. From 1991 and until 2007, Mr. Zwyer served in various positions with Viforpharma AG (SWX: VIFN) (then known as Vifor (International) Inc.), most notably serving as Executive Vice President (chief operating officer), leading the company’s global regulatory affairs, medical affairs, sales and marketing as well as business development teams. Mr. Zwyer speaks seven languages fluently. Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY.

GeorgeApostol, MD MS

CMO & Global Head R&D

George Apostol

Dr. Apostol’s career spans more than 20 years in pharma industry and consists of a broad drug development expertise across early, middle and late phases of development at the global R&D organizations of Eli Lilly, Pfizer, Abbott, Novartis, Shire and Endo.

His main areas of capability include orphan diseases in CNS, in particular Fragile X Syndrome, Alagille Syndrome, but also ADHD, anxiety, depression, migraine, Parkinson’s and schizophrenia. He has built multiple drug development teams both in the US and Europe, several receiving distinguished corporate R&D awards and achieving multiple regulatory approvals in US, EU and Japan. He holds a MD degree from the Carol Davila Medical School in Romania and a MS in Clinical Research from University of Minnesota.

EricKonofal, MD, PhD

Chief Scientific Officer and Co-Founder

Eric Konofal

A co-founder of the company with a deep knowledge and experience in clinical and scientific research. He is also a drug-hunter & pipeline developer for sleep disorders as ADHD.

Dr. Konofal is a primary clinical and international scientific researcher, and is an accomplished drug hunter and drug pipeline developer. He is a senior medical consultant for the Pediatric Sleep Disorders Center at Robert-Debre University of Paris (APHP). Dr. Konofal served as Principal Clinical Investigator at the Clinical Pharmacology & Pharmacogenetic Department at Robert-Debre University of Paris. His research has focused on brain- and iron-dopamine interactions in subjects with neurological sleep disorders (RLS, PLMS), and ADHD. Additionally, Dr. Konofal served as a consultant at the sleep disorder center of Pitié-Salpêtrière University Hospital Group (APHP), specializing in ADHD, RLS, PLMS and CDH. He initiated previous studies based on iron and its role in the pathophysiology of ADHD, and has conducted extensive research on the relationship between the brain and iron.

He launched a clinical trial on the efficacy of mazindol in children with ADHD (clinicaltrials.gov identifier: NCT00508677) and obtained the U.S. patent for mazindol in the treatment of ADHD. Dr. Konofal wrote the scientific rationale for Nolazol® and discovered the pharmacological profile of mazindol and its orexin-2 receptor binding properties. He has authored over 70 peer-reviewed publications in the area of sleep disorders and other CNS diseases.

‍

NEWS


NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Mar 31, 2025

NLS Pharmaceutics CEO Issues Letter to Shareholders

Mar 10, 2025

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Feb 27, 2025

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 25, 2025

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 25, 2025

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Feb 10, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Jan 31, 2025

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

Jan 30, 2025

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Jan 28, 2025

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Jan 16, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Shar…

Jan 8, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

Dec 30, 2024

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

Dec 19, 2024

NLS Pharmaceutics CEO Issues Letter to Shareholders

Dec 11, 2024

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

Dec 4, 2024

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

Dec 3, 2024

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

Nov 18, 2024

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Nov 4, 2024

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

Oct 28, 2024

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

Oct 21, 2024

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND TWO HUNDRED FIFTY USD BY LFG EQUITIES CORP FOR A ONE DAY NLSP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

SHPH

Sponsored by Sideways Frequency, LLC

Read the Investor Presentation HERE

https://player.vimeo.com/video/784819528?badge=0&autopause=0&player_id=0&app_id=58479

________________________

Hello Everyone,

Today’s profile shot up early on and exploded double digits before coming back down. We are certainly operating in volatile markets.

Let’s switch it up a bit today and give you tomorrow’s ticker ahead of time, while the after hours markets are still open.

Put SHPH on your screen right away and watch it immediately as we head into the last session of the week.

Founded in 2012 by faculty members of Georgetown University Medical Center, Shuttle Pharma is a discovery and development-stage specialty pharmaceutical company focused on enhancing outcomes for cancer patients undergoing radiation therapy (RT).

Dedicated to advancing therapies that maximize RT effectiveness while minimizing side effects, the company seeks to improve cancer treatment strategies. By developing radiation sensitizers, the goal is to increase cancer cure rates, extend patient survival, and enhance quality of life—whether used as a primary treatment or in combination with surgery, chemotherapy, and immunotherapy.

Shuttle Pharmaceuticals is dedicated to pioneering the next generation of radiation oncology treatments, aiming to transform cancer care. Achieving this goal requires innovation, expertise, and an unwavering commitment to scientific progress.

Through strategic collaborations and cutting-edge research, efforts are focused on pushing the boundaries of cancer treatment. By enhancing the effectiveness of radiation therapy, the mission is to improve patient outcomes, extend survival, and offer new hope to millions impacted by cancer worldwide.

Top Reasons to Have SHPH on Your Radar

Expanding Oncology Market: The global oncology market is projected to reach $903.81 billion by 2034,* presenting a massive growth opportunity for innovative cancer therapies.

Lead Candidate with Strong Potential: Ropidoxuridine (IPdR), a radiation sensitizer, seeks to enhance the effectiveness of radiation therapy for aggressive cancers like glioblastoma.

Orphan Drug Designation: IPdR has received FDA Orphan Drug Designation, which may provide market exclusivity upon approval, increasing its commercial potential.

  • 04Pipeline of Therapeutic Candidates : In addition to Ropidoxuridine, three lead candidates are in development for the treatment of solid tumors, including breast cancer, lung cancer, and multiple myeloma.
    • SP-2-225: A selective HDAC6 inhibitor, integral for antigen presentation by macrophages to T-lymphocytes.
    • SP-1-303: A Class I HDAC inhibitor with preferential efficacy against ER-positive cancers.
    • SP-1-161: A lead candidate that activates the ATM gene, which plays a critical role in DNA damage response and repair.

Growing Radiation Therapy Market: With 800,000 U.S. cancer patients receiving RT annually, and the global radiation therapy market expected to reach $12.93 billion by 2034,* demand for radiation sensitizers is increasing.

Diagnostics Expansion (PSMA-B Ligand, PC-Rad Test): SHPH is advancing next-generation diagnostics, including PSMA-B Ligand for prostate cancer imaging and PC-Rad Test, a novel diagnostic tool for precision radiation therapy.

Debt Level Advantage: SHPH has more cash than its total debt, strengthening its financial position and reducing risks for investors.  

Strategic Partnerships & Collaborations: Partnering with Georgetown University Medical Center, UNC Medical Center, UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network Cancer Institute, and Miami Cancer Institute to advance clinical trials and research.

Positioned for Growth: The company appears well-positioned to capitalize on increasing demand for radiation sensitizers and advanced cancer treatments.

Potential First-Mover Advantage: As a company focused on improving radiation therapy outcomes, SHPH may secure an early lead in a growing and underserved market segment.

The Growing Cancer Burden and the Critical Need for Advanced Therapies

Cancer remains a major global challenge, with 20 million new cases and 9.7 million deaths recorded in 2022. One in five people develop cancer in their lifetime, and survival rates vary significantly. Prostate cancer, the second most diagnosed cancer among men, caused 396,000 deaths in 2022, with cases expected to rise to 2.4 million annually by 2040 *. This growing burden highlights the urgent need for improved treatments.

Rising Demand for Radiotherapy and Sensitizers

Radiotherapy is a key cancer treatment, with an estimated 10 million new patients needing it in 2022. By 2050, this number could rise to over 21 million . In the U.S., 800,000 cancer patients receive radiotherapy annually, half with curative intent. The demand for radiation sensitizers is expected to grow by over 22% in the next five years, creating a significant market for innovations that enhance treatment outcomes.

The Urgent Need for Better Glioblastoma Treatments

Glioblastoma (GBM), the most aggressive brain cancer, affects 3.19 per 100,000 people globally. Standard treatments—surgery, radiotherapy, and chemotherapy—face high recurrence rates, leading to poor patient outcomes. New approaches are essential to improve survival and quality of life.

Advancing Innovation in Cancer Care

With rising cancer cases and treatment limitations, the need for effective therapies is greater than ever. Radiation sensitizers present an opportunity to enhance radiotherapy’s impact, improve survival rates, and address treatment resistance, shaping the future of cancer care.

Therapeutics

Ropidoxuridine

Ropidoxuridine (IPdR) is our lead candidate radiation sensitizer for use in combination with radiation therapy (RT) to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.

We have received Orphan Drug Designation from the FDA for IPdR, providing potential marketing exclusivity upon first FDA approval for treatment of the disease.

Ropidoxuridine (IPdR) is an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and the cells become more sensitive to the effects of RT. The mechanisms underlying our candidate agents have been attributed to incorporation of IUdR, a metabolite of IPdR, into DNA, yielding reactive uracil free radicals that cause lethal DNA double strand breaks following radiation exposure.

HDAC Inhibitors

Shuttle Pharma’s HDAC inhibitors target cancer cell growth while sparing normal cells, regulating gene expression to restore tumor suppressor function. With over 20 patents, three lead candidates focus on treating solid tumors, including breast and lung cancer. These molecules enhance radiation sensitization, immune response activation, and precision oncology advancements.

Diagnostics

PSMA-B Ligand

PSMA-B Ligand is a novel boron-containing molecule designed for prostate cancer diagnosis and therapy. With strong PSMA binding, it aims to enhance proton radiation therapy and serves as a PET diagnostic and targeted treatment. Preclinical studies and a research partnership with UCSF aim to advance its development as a theranostic solution.

PC-Rad Test

The PC-Rad Test aims to address the unmet need for a predictive, minimally invasive blood test to assess prostate cancer patients’ responses to radiation therapy. Through licensed IP from Georgetown University, this biomarker program seeks to personalize treatment decisions, improve outcomes, and enhance patient-clinician decision-making in prostate cancer care.

Strategic Agreements

We have developed important strategic agreements and contractual relationships with academic institutions for access to resources such as intellectual property, core facilities and contracting relationships. Our relationships have included:

University of California, San Francisco (UCSF)

We entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of Shuttle Diagnostics, Inc.’s (a wholly-owned subsidiary of Shuttle Pharma) ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule. UCSF researchers, led by principal investigator, Robert Flavell, M.D., PhD., will aim to develop radiosynthetic methods for producing [18F]FPA-ACUPA probe; investigate cellular binding properties of [18F]FPA-ACUPA in PCa cell lines; and investigate the diagnostic potential of the probe across various PCa phenotypes. Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application with the US Patent and Trademark Office.

Georgetown University

Georgetown University is an internationally recognized educational and research university engaged in the discovery and development of new cancer diagnostics and therapeutics through the programs of the Lombardi Comprehensive Cancer Center. Shuttle Pharmaceuticals subcontracted clinical aspects of SBIR funded research to establish cancer cell lines from African-American patients and to develop predictive biomarkers for patient sensitivity to radiation late-effects.

Brown University

We have received an SBIR contract from the NIH to fund a Phase I clinical trial in collaboration with Brown University at the Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in patients with advanced gastrointestinal cancers. In connection with the trial, NCI approved the Phase I clinical protocol and provided drug and clinical data management support to Rhode Island Hospital. The Phase I clinical trial has been completed and the results support advancing Ropidoxuridine to Phase II clinical trials of brain tumors, sarcomas and other tumors.

University of Virginia

The University of Virginia is an internationally recognized educational and research university engaged in the discovery and development of new cancer therapeutics and has developed the “Atomic Radiation” intellectual property. Shuttle Pharmaceuticals’ scientists collaborate with scientists at the University of Virginia to sensitizers for use with proton radiation therapy.

George Washington Cancer Center

Collaborations between the Villagra lab at George Washington University and the Shuttle Pharmaceuticals’ lab resulted in a joint presentation at the October 2020 AACR Conference of research addressing: “Immune-mediated Tumor Growth Inhibition by Selective HDAC6 Inhibitor SP-2-225.” Dr. Villagra has served as a Scientific Advisor to Shuttle Pharmaceuticals with expertise in cellular signaling pathways, epigenetics and immunology since 2017. We also have a material transfer agreement for testing HDAC inhibitor effects in immune model systems

TCG GreenChem

TCG GreenChem Inc. is a sister company of TCG Lifesciences Pvt. Ltd. Both are a part of the TCG Group based in New York, NY and together a leading global Custom Research and Manufacturing Services (CRAMS) company for drug discovery, development and commercialization. They have a presence in the United States, India, and Japan. TCG GreenChem Founder and Chief Executive Officer, Chris Senanayake, PhD along with Executive Vice President and Global Head of Research and Development, Executive Vice President and Global Head of Research and Development joined Shuttle’s leadership team in 2020 to manufacture drug product for use in proposed clinical trials.

‍

NEWS


Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Mar 13, 2025

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Mar 12, 2025

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Mar 12, 2025

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Feb 26, 2025

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 21, 2025

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 7, 2025

Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

Dec 19, 2024

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Nov 26, 2024

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 29, 2024

Shuttle Pharma Pays Off Senior Secured Convertible Note

Oct 29, 2024

Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 29, 2024

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 28, 2024

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024

Oct 28, 2024

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 16, 2024

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Sep 11, 2024

Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

Sep 5, 2024

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Sep 4, 2024

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 28, 2024

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 26, 2024

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Aug 14, 2024

‍

MANAGEMENT TEAM

Christopher Cooper

Interim CEO

Mr. Cooper has more than 27 years of experience in management and finance, having worked in the oil and gas, telecommunications and technology industries. In addition to his appointment as Interim Co-CEO of the Shuttle Pharma, Mr. Cooper also serves as President, CEO and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company with operations in Latin America, positions he has held since 2017. From 2010 until 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., a Vancouver, British Columbia-based oil and gas company, where he was responsible for overseeing day to day operations, financial reporting, and oversaw acquisitions and debt and equity financing. From 1998 until 2010, Mr. Cooper served as a Corporate Consultant to various companies in the technology and resources sectors, oversaw restricting activities for several distressed public companies, and was responsible for raising more than $100 million in debt and equity for his clients. Mr. Cooper received his MBA from Dowling College in 1995 and his BBA in Business Administration from Hofstra University.

Anatoly Dritschilo, MD

Chief Scientific Officer & Chairman

Dr. Dritschilo is a Company co-founder and has served as Chairman of the board of directors since December 2012. Dr. Dritschilo is an American Board of Radiology certified radiation oncologist with clinical experience treating cancer patients, directing basic science and clinical research projects and serving in administrative capacities as Department Chair at Georgetown University School of Medicine; Chief of Radiation Oncology at MedStar-Georgetown University Hospital; Medical Director of Georgetown University Hospital; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital and the MedStar Health Research Institute. His biotech experience includes co-founding Oncomed, Inc. and service as a member of the board of directors of Neopharm, Inc. His 250+ scientific publications and 20+ issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science (BS) degree in Chemical Engineering from the University of Pennsylvania, a Master’s Degree (MS) from the New Jersey Institute of Technology, a medical degree (MD) from the College of Medicine of New Jersey and completed residency training from the Harvard, Joint Center for Radiation Therapy.

Timothy Lorber, CPA

Chief Financial Officer

Mr. Lorber is a CPA with more than 40 years of professional finance experience, including 15 years with Legg Mason, Inc. (“Legg Mason”), one of the world’s larger public global asset management firms where he served as a Managing Director and Chief Accounting Officer until its sale in 2020. More recently, Mr. Lorber has served in leadership roles with several privately held businesses, overseeing finance, IT and HR functions. Prior to Legg Mason, Mr. Lorber served as Internal Audit Director of Freddie Mac and has also worked for several international public accounting firms.

Michael Vander Hoek, MHSA

Vice President, Regulatory

Mr. Vander Hoek serves as the Company’s Vice President, Regulatory. Previously he also served as the Company’s Chief Financial Officer, Prior to Mr. Tim Lorber joining the Company. Mr. Vander Hoek’s experience includes service as Director, Finance and Business Development at Georgetown Lombardi Comprehensive Cancer Center (“LCCC”), where he directed a five-year $221.9 million institutional commitment for cancer center research under an NCI-approved cancer consortium arrangement. His responsibilities included recruitment of scientists and senior leaders to address the Cancer Center’s mission. Previously, Mr. Vander Hoek served as Associate Director, Administration, at Georgetown’s LCCC, where he was directly responsible for t administrative operations and management of $216.9 million in institutional commitments to LCCC from Medstar Health, John Theurer Cancer Center (“JTCC”), and Georgetown University. Mr. Vander Hoek implemented an enterprise-wide clinical trial management system for Georgetown University and Medstar Health. Mr. Vander Hoek also served as the LCCC’s Chief Financial Officer negotiated research served as Vice-Chair, Planning and Administration, at MedStar Georgetown University Hospital. His financial management experience in publicly held companies includes Director of Managed Care Reimbursement for Critical Care America and Regional Controller for Laboratory Corporation of America (LabCorp) Mr. Vander Hoek holds a Master’s in Health Services Administration from George Washington University and a Bachelor of Arts in Biology and Psychology from Hope College.

Peter Dritschilo, MBA

President & COO

Mr. Dritschilo has served as our President and Chief Operating Officer since Shuttle Pharmaceuticals was formed in December 2012. He also served as our Chief Financial Officer until 2019. Mr. Dritschilo has more than 25 years of business management experience in medical services and cancer treatment. He has held administrative positions with Medstar-Rad America Georgetown University, Prince William Hospital/ Fauquier Hospital Cancer Center and Inova Health System’s Schar Cancer Institute. Mr. Dritschilo graduated from Georgetown University and received his MBA from George Washington University.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHT THOUSAND TWO HUNDRED FIFTY USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY SHPH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.